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This thesis explores the increasingly popular push by states to 
decriminalize and legalize marijuana and the resulting problems that raise 
concern about maintaining the current federal marijuana policy. This thesis 
conducts an analysis of various policy options to resolve conflicts that arise 
between recently enacted state legislation and federal criminal statutes, U.S. 
compliance with international treaties, and public safety. Utilizing Bardach’s 
eight-step method, this thesis compares three possibilities for policy 
recommendation. The first option is to maintain the status quo, or to continue a 
policy of relaxed federal enforcement. The second option is one of strict 
enforcement, essentially rolling back marijuana laws in the states and mandating 
compliance with current federal law. The third option is one of balancing the 
desires of the states while ensuring treaty compliance and public safety by 
rescheduling marijuana. 
The research shows that a rescheduling of marijuana, from Schedule I of 
the Controlled Substance Act to Schedule III, would protect marijuana’s access 
to those with a medical necessity while ensuring compliance with international 
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NOTE TO THE READER 
It should be noted that a majority of the data compiled in this thesis was 
published prior to 2016. The facts and findings reflected in that research, 
however, still provide a solid framework for an analysis of the problems and 
potential policy changes. The research and recommendations illustrated remain 
very timely due to the fact that the federal government has neither acted, nor 
stated its intent to act in the near-term, to remedy the conflicts perpetuated by a 
status quo acceptance of current federal marijuana policy.  
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EXECUTIVE SUMMARY 
On August 14, 1970, marijuana was added to Schedule I of the Controlled 
Substance Act. This, according to the Drug Enforcement Administration, 
effectively outlawed the substance federally, classifying the drug as having a high 
likelihood of abuse and no medical purpose. More than four decades later, the 
current trend is one of state voters and legislators enacting laws, which are in 
conflict with this prohibition, allowing for the use of marijuana medically, and in 
the case of some states, recreationally. What policy changes should the federal 
government consider in light of the ongoing state marijuana reforms? This thesis 
seeks to answer that question. 
The states’ push for marijuana decriminalization and legalization creates 
numerous problems and raise concerns about the current federal marijuana 
policy. These include inconsistent enforcement and prosecutorial guidance, 
noncompliance with standing international counter-drug treaties, and citizens in 
many states now acting as research subjects. 
The enforcement inconsistencies are illustrated by the fact that the U.S. 
Department of Justice, U.S. Department of Homeland Security, and countless 
state, local, and tribal law enforcement agencies police the frontlines of the effort 
to disrupt the tide of marijuana into the United States—all while more and more 
states vote to legalize the same substance. The marijuana decriminalization 
movement is creating a climate in which markets are being created for a 
substance that cannot be imported or cultivated in vast quantities legally, nor can 
the proceeds associated with its sale be processed through the legitimate 
banking system. 
In an attempt to illustrate the problems created by the states’ movement, 
this thesis reviews the current literature. This author conducted research to 
identify dimensions of the issues that may warrant policy changes. 
xviii 
This research explores four areas: 
a. The impact of state legalization of marijuana on international
accords that the United States has signed.
b. The impact of potential medical benefits on marijuana’s federal
classification and the impact of its classification on research.
c. The impact of marijuana legalization on health and public safety
risk.
d. The mechanism by which marijuana could be reclassified.
This thesis provides evidence that current states’ efforts are in conflict with 
federal marijuana law and policy in four areas explored: legal, law enforcement, 
medical, and health and public safety. The research shows that current 
scheduling stifles the very research that would tend to provide evidence for the 
need to reschedule marijuana in the first place. Similarly, current scheduling 
precludes the classification of marijuana as a prescription drug, which would 
provide for its regulation and compliance with both federal and international law. 
Evidence reported in this thesis shows a medicinal value of marijuana and 
also the dangers associated with its use early in life as well as impaired driving, 
and unknown THC content. While decriminalization appears to lead to greater 
use, even by those not legally authorized, there has been no evidence that 
increased marijuana use leads to an increase in Part-I (serious) reported criminal 
activity. The ambiguity in federal enforcement and the increasing tolerance by 
states and municipalities have started us down the road to rescheduling 
marijuana and THC. This thesis illustrates the need to finish the trip. 
This thesis explores three options for federal marijuana policy. The first is 
the status quo approach, or continued freedom of states to pass new laws while 
maintaining the relaxed enforcement of federal marijuana laws. Two other 
options considered are strict enforcement of federal marijuana law, and finally, 
the rescheduling of marijuana. 
The author’s advice to this federal administration and the yet-to-be 
appointed administrator of the Drug Enforcement Administration is to look at the 
 xix 
issue of marijuana legislation with a fresh eye and  also through the lens of all 
that has been learned over the last few years. This thesis seeks to highlight 
some of this research knowledge and impart it on those that are in positions of 
decision-making. The author has come to believe that the placement of 
marijuana in Schedule I was never meant to be permanent. As more and more of 
the original questions surrounding marijuana are answered and for more 
questions to be properly addressed in the future, the federal classification of 
marijuana must change. 
This thesis is framed by the fact that 45 states and territories have already 
passed some form of legislation that decriminalizes marijuana. Most of those 45 
states, the District of Columbia, and Guam have passed laws allowing for the 
medicinal use of marijuana. That is precisely what marijuana as a Schedule III 
drug would provide, along with treaty compliance, and the ability to use the 
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I. DIMENSIONS OF EMERGING CHANGES IN MARIJUANA 
POLICY 
A. RESEARCH QUESTION 
On August 14, 1970, marijuana was added to Schedule I of the Controlled 
Substance Act.1 This effectively outlawed the substance federally, classifying the 
drug as having a high likelihood of abuse and no medical purpose.2 More than 
four decades later, the current trend is one of state voters and legislators 
enacting laws that are in conflict with this prohibition, allowing for the use of 
marijuana medically, and in the case of some states, recreationally. What policy 
changes should the federal government consider in light of the ongoing state 
marijuana reforms? 
B. PROBLEM STATEMENT 
The states’ push for marijuana decriminalization and legalization creates 
numerous problems that raise concerns about the current federal marijuana 
policy. These include inconsistent enforcement and prosecutorial guidance, 
noncompliance with standing international treaties, and citizens in many states 
now acting as research subjects. 
The enforcement inconsistencies are illustrated by the fact that the U.S. 
Department of Justice, U.S. Department of Homeland Security, and countless 
state, local, and tribal law enforcement agencies police the frontlines of the effort 
to disrupt the tide of illegally imported marijuana into the United States. In 2013, 
the U.S. Senate passed a comprehensive immigration reform bill3 that included 
$30 billion in additional spending for border security and calls for an additional 
1 Sanjay Gupta, “Why I Changed My Mind on Weed,” CNN, August 8, 2013, 
http://www.cnn.com/2013/08/08/health/gupta-changed-mind-marijuana/.  
2 Drug Enforcement Administration, “DEA Controlled Substances Act,” accessed July 17, 
2017, https://www.dea.gov/druginfo/csa.shtmlTitle 21 USC.  
3 “S.744—113th Congress (2013–2014): Border Security, Economic Opportunity, and 
Immigration Modernization Act,” Congress, December 10, 2014, https://www.congress.gov/bill/
113th-congress/senate-bill/744.  
 2 
20,000 to 30,000 new Customs and Border Protection agents and officers. This 
proposed expansion came on the heels of an expansion that had already tripled 
the size of the Border Patrol between 2004 and 2012, with most of the buildup 
along the southwestern border of the United States with Mexico.4 This increased 
enforcement posture is in addition to the vast resources already expended by 
other agencies, including the Drug Enforcement Administration (DEA), in the fight 
against marijuana. However, at the same time, this country has been host to a 
growing domestic market for marijuana, as illustrated by the number of states 
that have sought to legalize it in some fashion (see Figure 1).  
Figure 1.  U.S. Marijuana Policy by State5 
 
                                            
4 Jeremy Slack, Daniel Martinez, Scott Whiteford, and Alison Lee, Border Militarization and 
Health: Violence, Death, and Security (Tucson, AZ: University of Arizona, 2013).  




There are several reasons why the U.S. federal government would likely 
opt against maintaining the current strategy of allowing individual states to pass 
legislation that is in direct conflict with federal mandates. Though the 10th 
Amendment to the U.S. Constitution precludes the federal government from 
commanding the states to criminalize marijuana, Title 21 of the U.S. Code 
outlaws its cultivation, importation, possession, transportation, sale, and use. The 
conflict between federal prohibition and state legalization sends a confusing 
message to the citizens of this country as well to the law enforcement personnel 
who must struggle to determine which side of the enforcement doctrine they must 
adhere. Several recent articles, including a New York Times piece6 in April of 
2015 and a Lincoln Memorial University, Duncan School of Law article7 illustrate 
the dilemma.  
The Times article8 describes the current situation of a former marijuana 
dispensary owner from Morro Bay, California. The subject, Charles Lynch, is 
caught between the state system that allowed him grow and sell marijuana from 
a storefront and the federal legal system that has recently convicted him of 
several counts of illegal drug dealing for the same activity. Mr. Lynch’s conviction 
appeal has highlighted just how bizarre things have become in marijuana 
legislation. An amendment to the 2015 House Appropriations Bill outlawed the 
Justice Department from spending any federal funds to prevent states from 
“implementing their own state laws that authorize the use, distribution, 
possession or cultivation of medical marijuana.”9 According to many in Congress, 
including conservative California Republican Representative Dana Rohrabacher 
                                            
6 Erik Eckholm, “Legal Conflicts on Medical Marijuana Ensnare Hundreds as Courts Debate a 
New Provision,” The New York Times, April 8, 2015, https://www.nytimes.com/2015/04/09/us/
medical-marijuana-dispensers-trapped-by-conflicting-laws.html?mcubz=2.  
7 Melanie M. Reid, “The Quagmire that Nobody in the Federal Government Wants to Talk 
About: Marijuana,” New Mexico Law Review 44, Rev. 169 (2014): 169–206, 
http://works.bepress.com/melanie_reid/11/.  
8 Ibid.  
9 “H.Amdt.332 to H.R.2578—114th Congress (2015–2016),” Congress, June 3, 2015, 
https://www.congress.gov/amendment/114th-congress/house-amendment/332/all-info.  
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who co-authored the bill, if the United States Attorney’s Office pursues 
prosecutions against individuals such as Mr. Lynch for activity that complies with 
state laws as quoted above, then it is the one violating federal law. In addition to 
the prosecutorial issues, to quote the Duncan Law School paper,10 “the lack of 
clarification has law enforcement and medical marijuana dispensary owners at a 
standoff, with the one side awaiting orders to shut down the businesses and the 
other risking a loss of livelihood if such an order is given.”11 
The same Controlled Substance Act of 1970 that gave us Title 21 also 
reaffirmed three international drug control treaties the compliance with which the 
United States and all other signatory nations, are charged. The three 
international drug control accords are the 1961 Single Convention on Narcotic 
Drugs as Amended by the 1972 Protocol,12 which limits marijuana “exclusively to 
medical and scientific purposes;” the 1971 Convention on Psychotropic 
Substances;13 and the 1988 Convention Against Illicit Traffic in Narcotic Drugs 
and Psychotropic Substances,14 which criminalizes all marijuana use that is not 
scientific in nature. 
Besides the contradictory legislation, conflicting enforcement protocols, 
and issues of non-compliance with international accords, the states that have 
opted for the legalization of marijuana have done little to regulate its content. 
Delta-9-tetrahydrocannabinol (delta-9-THC or THC) is a naturally occurring 
component of cannabis sativa L. (marijuana).15 THC is one of the compounds 
                                            
10 Ibid.  
11 Reid, “The Quagmire that Nobody,” 169.  
12 United Nations, Single Convention on Narcotic Drugs, 1961 (New York: United Nations, 
1961), https://www.unodc.org/pdf/convention_1961_en.pdf.  
13 United Nations, Convention on Psychotropic Substance, 1971 (New York: United Nations, 
1971), https://www.unodc.org/pdf/convention_1971_en.pdf.  
14 United Nations, 1988 Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic 
Substances (New York: United Nations, 1988), https://www.unodc.org/pdf/
convention_1971_en.pdf.  
15 Sarah R. Calhoun, Gantt P. Galloway , and David E. Smith, “Abuse Potential of Dronabinol 
(Marinol),” Journal of Psychoactive Drugs  30, no. 2 (1998): 197–196.   
 5 
that have been clinically demonstrated to possess therapeutic utility.16 It is also 
the compound that is scheduled by the DEA and the most widely cited compound 
in testing and recording potency. Whether for medicinal use or for the recreation 
of its users, THC content varies greatly in concentration in samples of seized 
marijuana.17  
Other issues created by the legalization efforts of states such as Colorado, 
Washington, and most recently California and Oregon are the boom in 
“narcotourism” and a potential increase in the number of impaired drivers 
operating motor vehicles within those jurisdictions and between states. As more 
and more states enter the clouded world of marijuana decriminalization and 
legalization, the need to provide some policy guidance to the federal government 
to rectify the problems created by the differing state laws becomes even more 
acute. 
C. LITERATURE REVIEW 
This thesis includes the author’s preliminary review of the literature in an 
effort to identify dimensions of the issues that may warrant policy changes.  
1. This research explores four areas: 
a. The impact of state legalization of marijuana on international 
accords that the United States has signed. 
b. The impact of potential medical benefits on marijuana’s 
federal classification and the impact of its classification on 
research. 
c. The impact of marijuana legalization on health and public 
safety risk. 
d. The mechanism by which marijuana could be reclassified. 
                                            
16 Janet E. Joy, Stanley J. Watson, Jr., and John A. Benson, Jr., eds., Marijuana and 
Medicine: Assessing the Science Base (Washington, DC: National Academy Press, 1999), 25.   
17 Zlatko Mehmedic, Suman Chandra, Desmond Slade, Heather Denham, Susan Foster, 
Amit S. Patel, Samir A. Ross, Ikhlas A. Khan, and Mahmoud A. ElSohly “Potency Trends of Δ9‐
THC and Other Cannabinoids in Confiscated Cannabis Preparations from 1993 to 2008,” Journal 
of Forensic Sciences 55, no. 5 (2010): 1209–1217.  
 6 
2. This review of the literature illustrates the following: 
a. Various state laws are in conflict with the current federal 
statutes.  
b. These inconsistencies have led to confusion and conflict 
between the enforcement policies of state, local, and federal 
law enforcement.  
c. Congress, while voting to fund counter-marijuana efforts, has 
also passed an appropriations bill precluding the federal 
government from using federal funds in contradiction of any 
state marijuana legalization efforts, adding to the confusion.  
d. The legalization efforts of the states have also potentially put 
the United States in non-compliance with international 
counter-drug treaties.  
e. The data suggests medical merit to marijuana but also 
reveals new dangers with increased decriminalization.  
f. The current scheduling of marijuana limits the availability of 
the substance for research purposes, hindering the very 
thing that could help guide federal policy changes.  
g. There is a mechanism in place by which the federal 
government could move to reclassify marijuana in another 
schedule of the Controlled Substance Act. 
1. The Impact of State Legalization of Marijuana on International 
Accords that the United States Has Signed 
The International Narcotics Control Board (INCB) is the body that is 
charged with overseeing the international compliance with the above-listed 
treaties. The INCB published an annual report in 2013 that stated that thanks to 
the passage of marijuana legalization reforms in the states of Colorado and 
Washington, the United States is “not in conformity with the international drug 
control treaties.”18 In its 2015 report, the INCB continues to call for the illegality 
of all dangerous drugs but does concede “States should be guided by the 
principle of proportionality in the determination of penalties.”19 The report goes 
                                            
18 Wells Bennett and John Walsh, Marijuana Legalization is an Opportunity to Modernize 
International Drug Treaties (Washington, DC: Brookings Institution, 2014).  
19 Ibid.  
 7 
on to say “the flexibility provided for by the conventions to offer alternatives to 
conviction or punishment for drug-related crimes of a minor nature remains 
underutilized.”20 
Researchers at the Brookings Institution state in their 2014 report that our 
federal government’s current “wait-and-see” position is not sustainable.21 The 
increase in the number of states that are decriminalizing marijuana use for 
recreational purposes is shifting the country further and further away from 
compliance with the treaties. Recent U.S. Department of Justice (DOJ) guidance, 
in the form of the August 2103 “Cole memo,” is essentially the new legislative 
framework.22 In the memo, Deputy Attorney General James M. Cole lays out 
prosecutorial guidelines for the enforcement of Title 21 marijuana laws, 
accounting for “whether a [marijuana operation in a legal state] is demonstrably 
in compliance with a strong and effective state regulatory system.”23 
It appears that the DOJ may be modeling the current policy after one that 
for years has looked nothing like the U.S. prohibition rather but that of the 
Netherlands. Marijuana is not legal in Amsterdam or any other city in the 
Netherlands. In fact, laws are on the books that make production and 
possession, even for personal use, a misdemeanor. The Netherlands are also 
party to the 1961 Single Convention on Narcotic Drugs as Amended by the 1972 
Protocol,24 the 1971 Convention on Psychotropic Substances,25 and the 1988 
                                            
20 International Narcotics Control Board, Availability of Internationally Controlled Drugs: 




22 James M. Cole, Guidance Regarding Marijuana Enforcement [memorandum] 
(Washington, DC: U.S. Department of Justice, 2013), http://www.dfi.wa.gov/documents/banks/
cole-memo-08-29-13.pdf.  
23 Ibid.  
24 Ibid.  
25 Ibid.  
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Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic 
Substances.26  
These conventions state that there has to be legislation in place 
criminalizing possession of controlled substances. However, it does not mandate 
the enforcement of these laws. In addition to this loophole, these conventions 
allow for drugs to be used for scientific and medical purposes. There has been a 
long-standing lack of enforcement that has rendered marijuana functionally legal 
in the Netherlands. Since 1976, the Dutch Ministry of Justice has applied what is 
called a gedoogbeleid, or tolerance policy. It has published an official set of 
guidelines with regard to the non-prosecution of “soft drugs,” including marijuana. 
Since the policy’s inception, the courts have ruled in many cases against 
prosecutorial efforts citing the tradition of non-enforcement.27 
In response to this policy of pseudo-legalization, an entire soft drug 
industry has evolved in the Netherlands. Narcotourism flourished as the streets 
of Amsterdam, which is filled with “coffee shops” pedaling various strains of 
marijuana instead of Arabica blends. Until recently, anyone in possession of less 
than 5 grams of marijuana or fewer than five plants would not be prosecuted. 
However, the Dutch have recently been rethinking their relaxed strategy and 
have begun implementing restrictions on the purchase and possession of 
marijuana by non-residents.28 
There are several approaches available to resolve the conflict between 
legalization and treaty-compliance in the United States. One option is suggested 
by the work of the Center for Effective Policy Management at Brookings. The 
authors advocate that the dilemma of treaty non-compliance presents an 
opportunity to craft changes to these international drug control treaties that would 
                                            
26 Ibid.  
27 Center for Public Impact, “The Dutch Policy on Marijuana Use: Continuity and Change,” 
November 23, 2016, https://www.centreforpublicimpact.org/case-study/dutch-policy-marijuana-
use-continuity-change/.  
28 Ibid.  
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“modernize” them to align with the growing international acceptance of 
marijuana.29 Another approach would be to innovate the way we comply with the 
treaties as that they are currently written. All three accords call for the outlawing 
of marijuana except for medical or scientific reasons. By accepting the research 
outlined in the reports from the Mayo Clinic30 and Koppel’s Systematic Review: 
Efficacy and Safety of Medical Marijuana in Selected Neurological Disorders,31 
there is an opportunity for rewriting our federal marijuana laws rather than the 
treaties.  
2. Impact of Potential Medical Benefits on Marijuana’s Federal
Classification, and the Impact of its Classification on Research
The national ban on marijuana began on August 14, 1970, when Assistant 
Secretary of Health, Dr. Roger O. Egeberg wrote a letter recommending the plant 
be classified as a Schedule I substance.32 In his rationale, Egeberg stated, 
Since there is still a considerable void in our knowledge of the plant 
and effects of the active drug contained in it, our recommendation 
is that marijuana be retained within Schedule I at least until the 
completion of certain studies now underway to resolve the issue.33 
In a 2008 position paper, the American College of Physicians demonstrated the 
dilemma that is currently facing the country. To quote Dr. Bostwick, in their 
paper, the authors “trod the middle ground between praising and demonizing 
botanical cannabis” when they stated it is “neither devoid of potentially harmful 
effects nor universally effective.”34 The group called for “sound scientific study” 
29 Bennett and Walsh, Marijuana Legalization. 
30 Michael J. Bostwick, “Blurred Boundaries: The Therapeutics and Politics of Medical 
Marijuana,” in Mayo Clinic Proceedings 87, no. 2 (2012): 172–186, https://www.ncbi.nlm.nih.gov/
pmc/articles/PMC3538401/.  
31 Barbara S. Koppel et al., “Systematic Review: Efficacy and Safety of Medical Marijuana in 
Selected Neurologic Disorders Report of the Guideline Development Subcommittee of the 
American Academy of Neurology,” Neurology 82, no. 17 (2014): 1556–1563.  
32 Gupta, “Why I Changed My Mind.” 
33 Ibid. 
34 Bostwick, “Blurred Boundaries.” 
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and “dispassionate scientific analysis.”35 It is this further study that is lacking, 
due profoundly to the fact that marijuana is Schedule I. We find ourselves in a 
quagmire highlighted by Dr. Douglas Fields in his article entitled “The Absurdity 
of Medical Marijuana.” In the article, he discusses the need for further research to 
determine if marijuana should be reclassified coupled with an absurd lack of the 
plant material available for research due to its very classification.36 Marijuana 
classification by the Controlled Substance Act37 places it in the category of those 
substances that do not show any accepted medical use. In spite of centuries of 
prescription, it fails to rate on par with the likes of other highly abused substances 
that have shown some medical benefit, such as opioids, which are derived from 
the opium poppy; cocaine, which is derived from the coca plant; close 
methamphetamine analogs, such as dextroamphetamine and methylphenidate; 
or even barbiturates and benzodiazepines. All of these substances are currently 
listed in Schedule II. Schedule II drugs are those with “high potential for abuse, 
less abuse potential than Schedule I drugs, with use potentially leading to severe 
psychological or physical dependence.”38 The primary difference between 
Schedule I and II definitions is the allowance for Schedule II drugs to have some 
accepted medical use.39 
3. Impact of Marijuana Legalization on Health and Public Safety 
Risk 
The White House has an Office of National Drug Control Policy (ONDCP). 
The ONDCP published a fact sheet in 2010 that listed several risks of marijuana 
                                            
35 PJ Cohen, “Medical Marijuana: The Conflict between Scientific Evidence and Political 
Ideology, Part Two of Two,” Journal of Pain & Palliative Care Pharmacotherapy 23, no. 2 (2009): 
120–140.  
36 Douglas Fields, “The Absurdity of ‘Medical Marijuana,’” Brain Facts [blog], December 20, 
2014, http://blog.brainfacts.org/2014/12/the-absurdity-of-medical-marijuana/.  
37 Drug Enforcement Administration, “Controlled Substances Act,” accessed March 3, 2017, 
https://www.dea.gov/druginfo/csa.shtml.  
38 Drug Enforcement Administration, “Drug Scheduling,” accessed March 3, 2017, 
https://www.dea.gov/druginfo/ds.shtml.  
39 Ibid.  
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legalization. In a 2005 article in Journal of General Internal Medicine, Moore et al. 
note that these include “dependence, respiratory and mental illness, poor motor 
performance, and impaired cognitive and immune system functioning.”40 
Marijuana intoxication can cause “distorted perceptions, problems with thinking, 
problem solving, learning, and memory.”41 According to Moore et al., “Studies 
have shown an association between marijuana use and increased rates of 
anxiety, depression, suicidal thoughts, and schizophrenia.”42 In addition, 
marijuana smoke has been shown to contain “50–70 times more carcinogenic 
hydrocarbons than tobacco smoke.”43 A 2011 study by the Partnership for Drug-
Free Kids and the MetLife Foundation illustrated that heavy marijuana use within 
                                            
40 Brent A. Moore et al., “Respiratory Effects of Marijuana and Tobacco Use in a U.S. 
Sample,” Journal of General Internal Medicine 20, no. 1 (2005): 33–37. Also see Donald P. 
Tashkin, “Smoked Marijuana as a Cause of Lung Injury,” Monaldi Archives for Chest Disease 63, 
no. 2 (2005): 93–100.  
Other evidence on the effect of marijuana on lung function and the respiratory system, and 
the link with mental illness, can be found in expert reviews offered by Wayne D. Hall and Rosalie 
L. Pacula, Cannabis Use and Dependence: Public Health and Public Policy (Cambridge, UK: 
Cambridge University Press, 2003).  
Room et al. write, “Cannabis use and psychotic symptoms are associated in general 
population surveys and the relationship persists after adjusting for confounders. The best 
evidence that these associations may be causal comes from longitudinal studies of large 
representative cohorts.” Furthermore, they also write, “animal studies suggest that high doses of 
cannabis extracts and of THC impair immune functioning.” Robin Room et al., Cannabis Policy: 
Moving beyond Stalemate (Oxford: Beckley Foundation, 2009), 
http://archive.beckleyfoundation.org/Cannabis-Commission-Report.pdf.  
Also see Louisa Degenhardt, and Wayne Hall, “Is Cannabis a Contributory Cause of 
Psychosis?,” Canadian Journal of Psychiatry, 51 (2006): 556–565. “A major study examining 
young people and, importantly, a subset of sibling pairs was released in February 2010 and 
concluded that marijuana use at a young age significantly increased the risk of psychosis in 
young adulthood.” See John McGrath et al., “Association between Cannabis Use and Psychosis‐
related Outcomes Using Sibling Pair Analysis in a Cohort of Young Adults,” Archives of General 
Psychiatry, 67, no. (2010): 440–447.   
41 Harrison G. Pope et al., “Neuropsychological Performance in Long‐term Cannabis Users,” 
Archives of General Psychiatry 58, no. 10 (2001): 909–915.  
42 Theresa H. Moore et al., “Cannabis Use and Risk of Psychotic or Affective Mental Health 
Outcomes: A Systematic Review,” Lancet 370, no. 9584 (2007): 319–328.  
43 Ibid.  
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the preceding month increased 80 percent for the period from 2008 to 2011 (see 
Figure 2).44  
Of the 23 states that currently have marijuana laws, 12 of them have 
passed their respective legislation since 2008. The four states of Arizona, 
Delaware, Michigan, and New Jersey and the District of Columbia passed their 
marijuana-friendly laws during the years of reported increased use (see  
Figure 2). These facts indicate an increased use and lead one to conclude that 
that the increases could be the result of marijuana legalization in those 12 states 
to pass marijuana laws since 2008. 
Figure 2.  Prevalence of Marijuana Use 
 
THC is one of the two most medically relevant substances in marijuana.45 
THC provides medical relief but also causes marijuana’s psychoactive effects.46 
                                            
44 MetLife Foundation, The Partnership Attitude Tracking Study (New York: MetLife 
Foundation, 2012), http://www.drugfree.org/wp-content/uploads/2012/05/PATS-FULL-Report-
FINAL-May-2-PDF-.pdf.  
45 Bostwick, “Blurred Boundaries.”  
46 Ibid.  
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Its content varies greatly in concentration in samples of seized marijuana.47 Two 
potential risks involved in marijuana decriminalization are those of THC content 
and impaired driving. 
The synthetic THC content found in the only U.S. Food and Drug 
Administration (FDA)-approved synthetic cannabinoid, Marinol, is consistent. 
Federal law and regulation require that a regulated “drug’s chemistry must be 
known and reproducible.”48 Most jurisdictions opting for legalization are 
foregoing these drug safety mandates, acknowledging that there are no 
standards for growing processes or THC levels of marijuana. As of December 
2016, 45 states and the District of Columbia now allow for the medical use of 
marijuana. Of those states, only 17 have laws limiting the THC content or 
psychoactive effects.49 
Marijuana has seen rising levels of THC over the past 60 years of 
testing.50 For comparison, the national average of THC content in 1978 was 1.37 
percent, in 1988 it was 3.59 percent, and in 2008 it was 8.49 percent.51 The 
highest tested sample in a December 2008–March 2009 study recorded 22.04 
percent THC content. Though some marijuana advocates argue that the 
increases in THC level merely mean that smaller doses can be ingested,52 this 
logic does little to negate the potential for abuse. In addition, it is quite possibly 
the biggest risk that comes from unregulated and unknown THC levels. A recent 
                                            
47 Mehmedic et al., “Potency Trends of Δ9‐THC.”  
48 Jonathan P. Caulkins, Angela Hawken, Beau Kilmer, and Mark A. R. Kleiman, Marijuana 
Legalization: What Everyone Needs to Know (Oxford: Oxford University Press, 2012).  
49 National Conference of State Legislatures, “State Medical Marijuana Laws,” August 30, 
2017, http://www.ncsl.org/research/health/state-medical-marijuana-laws.aspx.  
50 Mahmoud A. ElSahly, Potency Monitoring Project, December 16, 2008–March 15, 2009 
(Oxford: MS: University of Mississippi, 2009), 104.  
51 Ibid.  
52 Ibid.  
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report from the Colorado State Department of Public Health reveals typical THC 
levels for marijuana in Colorado in the 20 percent range.53 
A 2015 RAND Corporation study of the correlations between the legality 
and acceptability of substances and their level of use shows that alcohol and 
cigarettes far outpace marijuana in reported use.54 This trend could potentially 
wane if illegality ceased to keep prices high and social acceptability low. Another 
report, published in Addiction in January of 2014, examined the marijuana use of 
fatally injured drivers. This study showed that the number of drivers testing 
positive for marijuana tripled between 1999 and 2010.55 Though the study tested 
merely for drug use and not a level of impairment, the tests were conducted on 
drivers involved in fatal traffic collisions. It should be noted that California was the 
first state to decriminalize marijuana in 1996, with the medical marijuana 
legislation passed by Proposition 215. Only six states that routinely test the 
toxicology of injured drivers were included in the study, California was one of 
them.56 Neither Colorado nor Washington was included. 
Another study from 2012, supported by the National Institutes of Health, 
conducted a “meta-analysis of nine different research studies.” The research 
found that drivers who “test positive for marijuana or report driving within three 
hours of marijuana use are more than twice as likely as non-marijuana impaired 
drivers to be involved in motor vehicle crashes.”57 Though there is no data with 
regard to amount of marijuana ingested or the potency, the findings point to 
increased likelihood of traffic collisions for drivers that have tested positive for 
                                            
53 Colorado Department of Public Health and Environment, Monitoring Health Concerns 
Related to Marijuana: 2014 (Denver, CO: Colorado Department of Public Health and 
Environment, 2014), https://drive.google.com/file/d/0B0tmPQ67k3NVVUhScGZUSWpGQ1k/view.  
54 Deborah S. Hasin et al., “Medical Marijuana Laws and Adolescent Marijuana Use in the 
USA from 1991 to 2014: Results from Annual, Repeated Cross-sectional Surveys,” The Lancet 
Psychiatry 2, no. 7 (2015): 601–608.  
55 Joanne E. Brady and Guohua Li, “Prevalence of Alcohol and Other Drugs in Fatally Injured 
Drivers,” Addiction 108, no. 1 (2013): 104–114.  
56 Ibid. 
57 Mu-Chen Li et al., “Marijuana Use and Motor Vehicle Crashes,” Epidemiologic Reviews 
34, no. 1 (2011): 65–72.  
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marijuana or admitted use within three hours of getting behind the wheel, which 
indicates increased risk of traffic-related injury. 
Another 2014 study looks at the state of Colorado before and after its 
legalization of marijuana. Compiling data from compiled from 1994 to 2011, the 
researchers compared fatal motor vehicle crashes in Colorado and in 34 states 
(at the time) without “medical marijuana” laws.58 Colorado passed its first 
marijuana law in mid-2009. The researchers found that “fatal motor vehicle 
crashes in Colorado involving at least one driver who tested positive for 
marijuana accounted for 4.5 percent in the first six months of 1994.”59 This 
percentage “increased to 10 percent in the last six months of 2011.”60 The 
increase was significantly greater in Colorado than in any of the 34 non-medical 
marijuana states.61  
4. The Mechanism by Which Marijuana Could Be Reclassified 
Federally 
The classification of drugs and narcotics within the Schedule of Controlled 
Substances is the responsibility of the DOJ and the DEA. Per the Congressional 
Research Service (CRS), the “placement of drugs or other substances into 
schedules under the Controlled Substance Act (CSA) is based upon the 
substance’s medical use, potential for abuse, and safety or dependence 
liability.”62 The act further provides a mechanism for substances to be added to a 
schedule, and thusly controlled; decontrolled, or removed from the scheduling 
framework altogether, and rescheduled or transferred from one schedule to 
another.  
                                            
58 Stacy Salomonsen-Sautel et al., “Trends in Fatal Motor Vehicle Crashes before and after 
Marijuana Commercialization in Colorado,” Drug and Alcohol Dependence 140 (2014): 137–144, 
https://www.ncbi.nlm.nih.gov/pubmed/24831752.  
59 Ibid. 
60 Ibid.  
61 Li et al., “Marijuana Use.”  
62 Congressional Research Service, The Legal Process to Reschedule Marijuana 
(Washington, DC: Congressional Research Service, 2012), https://fas.org/sgp/crs/misc/
reschedule.pdf.  
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Quoting the Controlled Substance Act, a CRS 2015 legal sidebar entitled, 
The Legal Process to Reschedule Marijuana, states, 
There are two general methods by which marijuana may be 
rescheduled: 
1. Congress may choose to enact legislation amending the CSA. 
Congress placed marijuana in Schedule I when it enacted the CSA 
in 1970 and retains the authority to move the drug to a less 
restrictive schedule or to remove the drug from the CSA framework 
entirely. 
2. The Drug Enforcement Agency (DEA) may administratively move 
marijuana to a lower schedule or remove it entirely. The CSA 
authorizes the DEA (by delegation from the Attorney General) to 
“transfer between schedules” any drug that meets the criteria for 
inclusion in the “schedule in which such drug is to be placed,” or to 
“remove any drug...from the schedules” if it “does not meet the 
requirements for inclusion in any schedule.” 
In addition to these basic scheduling criteria, the CSA lays out eight 
factors that must be considered in any scheduling determination.  
§811 of the CSA clearly defines the eight criteria noted above. Subchapter 
C, entitled “Factors determinative of control or removal from schedules” 
mandates that the following criteria be applied to any substance under 
consideration for CSA scheduling placement.63 
1. Its actual or relative potential for abuse. 
2. Scientific evidence of its pharmacological effect, if known. 
3. The state of current scientific knowledge regarding the drug or 
other substance. 
4. Its history and current pattern of abuse. 
5. The scope, duration, and significance of abuse. 
6. What, if any, risk there is to the public health. 
7. Its psychic or physiological dependence liability. 
                                            
63 21 USC §811.  
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8. Whether the substance is an immediate precursor of a substance
already controlled under this subchapter
D. CHAPTER CONCLUSION 
The purpose of this literature review was to identify dimensions of the 
marijuana legislation problem that may warrant policy changes.  
The research illustrates that: 
a. Various state laws are in conflict with the current federal statutes.64
b. These inconsistencies have led to confusion and conflict between
the enforcement policies of state, local, and federal law
enforcement.65
c. While voting to fund counter-marijuana efforts, Congress also
passed an appropriations bill precluding the federal government
from using federal funds in contradiction of any state marijuana
legalization efforts, which adds to the confusion.66
d. The legalization efforts of the states have also potentially put the
U.S. in non-compliance with international counter-drug treaties.67
e. The data suggests medical merit to marijuana,68 but also reveals
new dangers with increased decriminalization.69
f. The current scheduling of marijuana limits the availability of the
substance for research purposes, hindering the very thing that
could help guide federal policy changes.70
g. There is a mechanism in place by which the federal government
could move to reclassify marijuana in another schedule of the
Controlled Substance Act.71
64 National Conference of State Legislatures, “State Medical Marijuana Laws.”  
65 Cole, Guidance Regarding Marijuana.  
66 “Amendment Text: H.Amdt.748—113th Congress (2013–2014),” Congress, 2014, 
https://www.congress.gov/amendment/113th-congress/house-amendment/748/text. 
67 Bennett and Walsh, Marijuana Legalization.  
68 Koppel et al. “Systematic Review.”  
69 Li et al., “Marijuana Use.”  
70 Fields, “The Absurdity of ‘Medical Marijuana.’”  
71 “Title 21 United States Code (USC) Controlled Substances Act,” Drug Enforcement 
Agency, accessed April 29, 2017, https://www.deadiversion.usdoj.gov/21cfr/21usc/811.htm. 
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The problem facing the country can be summed up with one line in Dr. 
Bostwick’s Mayo Clinic report. He says, “In sum, marijuana offers the recreational 
substance abuse version of caveat emptor.”72 However, a buyer-beware 
approach to marijuana does not appear to be in the best interests of the country. 
By identifying the dimensions of the problem that may warrant policy changes, 
opportunities will emerge for the federal government to craft new policies to 
protect the American people. 
E. RESEARCH DESIGN 
The research methodology for this research is policy analysis. I used the 
eight-step process as outlined by Eugene Bardach in his book, A Practical Guide 
for Policy Analysis (see Figure 3).73  
Figure 3.  Eight-Step Policy Analysis74 
 
In his book, Bardach tells us that defining the problem is critical because it 
gives us a reason for the work we are undertaking and provides a sense of 
                                            
72 Bostwick, “Blurred Boundaries.”  
73 Ibid.  
74 Adapted from: Eugene Bardach and Eric M. Patashnik, A Practical Guide for Policy 
Analysis: The Eightfold Path to More Effective Problem Solving (Washington, DC: CQ press, 
2015).  
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direction.75 He explains that it is often helpful when defining a problem “to think 
in terms of deficit or excess.”76 The abundance of state laws that are in direct 
conflict with federal drug statutes creates a chaotic environment. This chaos 
flows from the fact that while states are voting to decriminalize and legalize 
marijuana, Title 21 of the U.S. Code still forbids its use for any purpose.77 Use 
for any purpose other than medical or research puts the United States in non-
compliance with international counter-drug treaties.78 Classification of marijuana 
as a Schedule I drug precludes the kind of robust, clinical research that is 
required to effectively mandate its regulation. The void in testing and regulation in 
those states that have opted for some form of legalization leads to increased risk 
of overdosing, accidental ingestion, and impaired driving. The marijuana laws 
passed by individual states have created uncertainty, inconsistency, and 
potential danger.  
Assembling evidence of the problem and potential policy solutions involve 
gathering the existing data. One key factor in my evidence collection is be to, as 
Bardach puts it, “free my captive mind.”79 As a law enforcement and homeland 
security professional, it was imperative that the author follow Bardach’s advice to 
seek research and data from sources with whom one would expect to disagree—
”the more sharply the better.”80 
The analysis leads to the construction of alternatives in federal marijuana 
policy. Just as the defining of the problem and the scope of research required the 
application of a lens for what criteria the author is using, the alternative policy 
recommendations are similarly presented with certain criteria in mind. The 
                                            
75 Bostwick, “Blurred Boundaries.”  
76 Bardach and Patashnik, A Practical Guide, 2.  
77 “U.S. Code: Title 21—Food and Drugs,” Legal Information Institute, accessed April 29, 
2017, https://www.law.cornell.edu/uscode/text/21.  
78 Ibid.  
79 Bardach and Patashnik, A Practical Guide, 16.  
80 Ibid.  
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answer to the problem of conflicting state and federal marijuana legislation is not 
one that can be answered by a single policy shift. A policy recommendation may, 
when applied to some criteria, be complimentary of some states’ laws, and when 
applied to other criteria may conflict with the same states’ paths. The two are not, 
as Bardach puts it, “mutually exclusive.”81 
A recommendation from Bardach that is applicable to this thesis is for 
each of the criterion to always include the approach of “let present trends (or 
business-as-usual) continue undisturbed.”82 This is never meant to “do nothing,” 
but rather, in this case for example, that it may not be the proper time in the 
evolution of a current state’s evolving marijuana legislative process to intervene. 
There may, for example, be solutions pending already for relaxing prohibitions on 
the research of marijuana. The key is to look at what specifically state 
decriminalization laws are doing to create the problem defined and what policy 
options flow from those effects. The goal of this thesis is to add “menu items” to 
the list of informed policy options that the federal government has in resolving the 
problem. 
Step four of the research methodology is to select the criteria to evaluate 
the potential alternatives.83 Though the criteria may be the same in name as 
those used to define the problem and frame the research, in this step they are 
used differently. Bardach describes a two-fold path to policy recommendation, 
one that is both analytical and evaluative.84 The criteria applied in this exercise 
may be legal, law enforcement, international, political, and medical, just as in the 
first step. When gathering data to be used in constructing alternatives, these 
criteria were applied analytically. That is to say that I used a more objective and 
open-minded approach to my research to gather a fair, if not impartial, 
representation of the existing research.  
                                            
81 Ibid.  
82 Ibid., 18.  
83 Ibid., 16.  
84 Ibid., 31.  
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As Bardach describes it, this step is where “we expect to see subjectivity 
and social philosophy to have freer play.”85 When evaluating each of the policy 
alternatives in terms of the criteria, it now becomes in terms of the projected 
outcomes and the benefits that each may bring. The author defines groups of 
individuals, or stakeholders, in this step. When applying the international 
criterion, for example, the author has to take into account what it means for the 
federal government to be in non-compliance with an international treaty and 
ultimately what that could mean for individual states. From a law enforcement 
perspective, there are many stakeholders; the taxpayers in “legal” states that 
have presumably voted for relaxed marijuana enforcement and the officials 
charged with protecting people from the dangers posed by bad or incomplete 
legislation. 
Now that the criteria are selected, in terms of who is affected by potential 
outcomes, it is time to project those outcomes. Bardach begins his chapter by 
reminding the analyst that policy recommendations are for the future, not the 
present or the past, so certain assumptions have to be made about projecting 
them. He also reminds us that projecting the outcomes means being realistic.86 
There are logistical and political constraints that should be factored in when 
seeking to provide policy recommendations that are realistic. 
Magnitude estimates are helpful in projecting many of the outcomes in this 
study. There are hard numbers that describe potential tax revenue, for instance, 
or percentages in likelihood of impaired driving. The use of scenario writing may 
prove to be the best way to project the various recommendations. Bardach 
reminds us of the importance in countering what he calls the emergent-features 
problem by viewing the projected policy outcomes from various points of view. By 
examining the projections from the perspective of various stakeholders, the 
viability of those projections are better illustrated in each scenario.  
                                            
85 Ibid., 32.  
86 Ibid., 47.  
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Bardach’s next step in the policy analysis is to confront the trade-offs. This 
step involves focusing on the outcomes and making comparisons to what 
Bardach refers to as the “base case.”87 The base case in this analysis is the 
status quo. What the outcomes would be if there were no changes in federal 
policy is the first outcome scenario for each alternative. It is helpful in this study 
to focus on just a few states. For example, Colorado has been a leading force in 
providing its own alternatives to the federal policy of prohibition. Examining the 
projected outcomes of various federal policy changes, in terms of Colorado, 
offers trade-offs that can be applied to the country as a whole. 
In preparation of the next step, Bardach instructs the analyst at this point 
to “focus, narrow, and deepen”88 the analysis of the most viable policy options. It 
is at this stage that Bardach tells us to think very seriously in terms of the 
requirements to get the policy alternatives adopted and the mechanics by which 
the policy could and would be implemented in the future. 
Step seven in the process is to “decide!” At this stage, Bardach tells the 
analyst to imagine that she or he is the decision maker, the one who is going to 
be deciding whether to implement the policy recommendations.89 He tells us to 
think of it terms of plausibility. If an analyst does not believe enough in his or her 
own recommendations to implement them, then the analyst will not be able to 
convince others of their value. Any hesitation that the analyst feels could be due 
to insufficient analysis of the trade-offs or an illustration of implementation 
problems that the analyst still needs to address. 
The final step in the policy process is to tell the story. Bardach tells us to 
first test our own understanding of the conclusions by attempting to explain the 
policy answers to the problem defined in one minute or less. Bardach refers to 
                                            
87 Ibid., 66.  
88 Ibid., 68.  
89 Ibid., 69.  
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this exercise as the “Grandma Bessie” test.90 This test is one that is applied in 
the thesis process at every meeting with the advisors. The audience for the 
recommendations of this thesis is the federal government. The “story” winds from 
the history of the problem, through the gathering of pertinent data, to constructing 
alternatives, and analyzing their potential outcomes and trade-offs. 
  
                                            
90 Ibid., 70.  
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II. THE NATURE OF THE PROBLEM: RECENT CHANGES IN
MARIJUANA POLICY HAVE CREATED INCONSISTENCIES AND 
CONFLICT 
The debate over marijuana in this country is not a new one. In fact, 
marijuana has been discussed since the beginning of recorded time. In his 2012 
article, Dr. J. Michael Bostwick provides a brief history of marijuana, its 
therapeutics, and use.91 He reports that for “five millennia there is recorded use 
of marijuana to treat a variety of ailments. The first medical use probably 
occurred in Central Asia and later spread to China and India.”92 The website 
ProCon provides examples of historical use of medicinal marijuana; it explains,  
The Chinese emperor Shen-Nung is known to have prescribed it 
nearly five thousand years ago. Between 2000 and 1400 BC, it 
traveled to India and from there to Egypt, Persia, and Syria. 
Greeks, and Romans valued the plant for its ropelike qualities as 
hemp, and it also had medical applications.93  
Marijuana use was not prevalent in western civilizations during medieval times, 
though it was valued for its fibers, hemp, to make rope, cloth, and paper.94 In 
fact, the American Declaration of Independence is purported to have been 
drafted on hemp-based paper.95 
Irish doctors who learned of the plant’s therapeutic properties while in 
India began prescribing the drug to their patients.96 In the United States, 1860 
saw the first documented research study, as the Ohio State Medical Society 
conducted the first official U.S. government study of cannabis, analyzing the 
91 Bostwick, “Blurred Boundaries,” 173. 
92 ““Historical Timeline: History of Marijuana as Medicine—2900 BC to Present,” accessed 
March 3, 2017, http://medicalmarijuana.procon.org/view.timeline.php?timelineID=000026.  
93 Ibid., 173.  
94 Allison Mack and Janet E. Joy, Marijuana as Medicine?: The Science Beyond the 
Controversy (Washington, DC: National Academy Press, 2001), 15. 
95 “What Kind of Paper was the Constitution Written On?,” U.S. Constitution Online, 
September 12, 2011, http://www.usconstitution.net/constfaq_a8.html.  
96 Mack and Joy, Marijuana as Medicine?,” 15. 
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medical literature and compiling a detailed list of conditions that “doctors had 
successfully treated with psychoactive hemp, ranging from bronchitis and 
rheumatism to venereal disease and postpartum depression.”97 That same year, 
physicians attending a national conference “reported success in using marijuana 
to treat chronic cough, gonorrhea, pain, and a variety of other conditions.”98 
By 1930, American pharmaceutical companies had begun bottling extracts 
of marijuana as a painkiller and sedative as well as manufacturing marijuana 
cigarettes.99 At the same time, the free flow of commerce and people across the 
U.S.-Mexico border brought the spread of marijuana use for recreational 
purposes.100 The first federal legislation that addressed marijuana use was the 
Uniform Narcotic Drug Act of 1932, which encouraged states to prohibit 
marijuana.101 By 1937, every state in the Union had passed some form of 
legislation outlawing marijuana use.102 In spite of the prohibitions, marijuana use 
continued to rise through the 1960s and 70s.103 
The federal ban on marijuana began on August 14, 1970, when Assistant 
Secretary of Health, Dr. Roger O. Egeberg wrote a letter recommending the plant 
be classified as a Schedule I substance,104 as listed in Title 21 of the U.S. 
Code.105 Schedule I drugs are those that law enforcement officers are tasked 
with enforcing the prohibitions on cultivation, importation, transportation, 
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possession, and use of. They are those drugs that have been identified by the 
DEA as “having no accepted medical use and a high potential for abuse.”106 
Other drugs classified as Schedule I are heroin, lysergic acid diethylamide (LSD), 
3,4-methylenedioxymetmaphetamine (ecstasy), methaqualone, and peyote.  
The same Controlled Substance Act of 1970 that gave us Title 21 also 
reaffirmed three international drug control treaties with which the United States, 
and all other signatory nations, are charged compliance.107 The INCB is the 
international body charged with monitoring the compliance of the treaty and 
assisting governments in upholding their treaty obligations. In its 2014 annual 
report, the INCB states that the recent legislation in Colorado and Washington 
are “not in conformity with the international drug control treaties” and that the 
United States must “ensure the full implementation of the international drug 
control treaties on its entire territory.”108 
In 1996, California became the first state to challenge the federal 
prohibitions on marijuana. Voters in the state passed Proposition 215, which was 
officially entitled “Compassionate Use Act of 1996.”109 It became the first 
medical marijuana legislation in the United States.110 It not only “allows patients 
with a valid doctor’s recommendation and the patients’ designated primary 
caregivers to possess and cultivate marijuana for personal medical use,” it has 
since been expanded to “protect a growing system of collective and cooperative 
distribution.”111 California has since added §11362.5 to the California Health and 
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Safety Code.112 To date, a total of 28 states, the District of Columbia, and Guam 
all now have laws allowing medical marijuana programs.113 In November 2012, 
voters in Washington state114 and Colorado115 and approved ballot measures 
that legalized the production, distribution, and possession of marijuana for 
recreational purposes. In the four years since, five more states and the District of 
Columbia have also voted to legalize the recreational use of marijuana.116 
The most recent DOJ guidance, in the form of the August 2013 “Cole 
memo,” is essentially the new federal marijuana legislative framework.117 In the 
memo, Deputy Attorney General James M. Cole lays out prosecutorial guidelines 
for the enforcement of Title 21 marijuana laws, accounting for “whether a 
[marijuana operation in a legal state] is demonstrably in compliance with a strong 
and effective state regulatory system.”118 
Besides the contradictory legislation, conflicting enforcement protocols, 
and issues of non-compliance with international accords, the states that have 
opted for the legalization of marijuana have done little to regulate its content. 
Delta-9-tetrahydrocannabinol (delta-9-THC or THC) is a naturally occurring 
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component of cannabis sativa L. (marijuana).119 THC is one of the compounds 
that have been clinically demonstrated to possess therapeutic utility.120 It is also 
the compound that is scheduled by the DEA and the most widely cited compound 
in testing and recording potency. Whether for “medicinal” use or for the 
recreation of its users, THC content varies greatly in concentration in samples of 
seized marijuana.121 The very research that Dr. Egeberg awaited and that could 
be used to show the efficacy and dangers of marijuana are stifled by the catch-22 
scenario created by marijuana’s current scheduling. Because it is Schedule I, 
marijuana is only available for research at one university campus in the country 
and only at certain potencies. 
Other issues created by the legalization efforts of states such as Colorado, 
Washington, and others are the boom in “narcotourism” and a potential increase 
in the number of impaired drivers operating motor vehicles within those 
jurisdictions and between states. The news is not all bad, however. There has 
been research conducted to examine whether marijuana use in young adults 
leads to greater involvement in criminal activity. A study published in 2014 
examined data from states with decriminalized marijuana from 1990–2006 and 
found no link between marijuana use and higher crime rates.122 Another positive 
side effect of the decriminalization of marijuana and the legitimization of the 
industry may be the tax revenue generated from its legal sale and purchase. A 
recent Brookings Institute report assessing the benefits of proposed marijuana 
legalization in Vermont offered projected tax revenue between $20 million and 
$75 million, annually.123 As more and more states enter the clouded world of 
marijuana decriminalization and legalization, the need becomes even more acute 
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to provide some timely and “balanced” (see Figure 4) policy guidance to the 
federal government to rectify the problems created by the differing state laws. 
Figure 4.  Marijuana’s Legal Future Still Hangs in the Balance124 
 
 
A. EVIDENCE: THE NATURE OF THE INCONSISTENCIES AND 
CONFLICT 
The author gathered data with regard to the nature of the inconsistencies 
and conflict as part of the review of literature. The evidence gathered is 
presented below to answer the questions raised through application of the 
following four specific, but overlapping, criteria: 
1. Legality: international and domestic 
a. What are the U.S. federal government’s responsibilities with 
regard to international drug control treaties?  
b. What are the implications of state marijuana legalization 
efforts on treaty compliance?  
c. Are there other countries that are struggling with the same 
inconsistencies and conflicts?  
d. What are the options for classification within the Schedule of 
Controlled Substances? 
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2. Impact on law enforcement
a. What is the current federal guidance for enforcement and
prosecution?
b. What is the current guidance to state, local, and tribal law
enforcement?
c. Are there links between marijuana abuse and other criminal
behavior?
3. Medical impact
a. Are there efficacies to marijuana use and at what potencies
and chemical compositions?
b. What would reclassifying marijuana potentially do for
research?
4. Impact on health and public safety risk
a. What are the potential dangers of marijuana use?
b. What effect does the shift in decriminalization and
legalization have on the risks associated with marijuana?
B. LEGALITY: INTERNATIONAL 
As already noted, there are three international treaties to which the United 
States is a signatory nation. That is to say that compliance requires legislation on 
the part of the countries involved. The United States passed such legislation in 
the form of the Controlled Substance Act.125 Prior to 1996, each of the 50 U.S. 
states had statutes mirroring the federal counter-drug statutes.126 Since the 
125 See 21 U.S.C. §801(7) (finding that “[t]he United States is a party to the Single 
Convention on Narcotic Drugs, 1961, and other international conventions designed to establish 
effective control over international and domestic traffic in controlled substances.”); “21 U.S.C. 
§802a (2), (3) (finding that, among other things, the 1971 Convention on Psychotropic
Substances is not self-executing, and expressing intent of Congress that the amendments made 
by this Act, together with existing law, will enable the United States to meet all of its obligations 
under the [1971] Convention and that no further legislation will be necessary for that purpose; 
observing that control of psychotropic substances under the 1971 Convention would be carried 
out pursuant to the CSA’s framework);” H.R. Rep. 112–324 (I) at 3 (2011) (stating that “[t]he 
United States is a signatory to two leading international drug treaties: the 1961 Single Convention 
on Narcotic Drugs and the 1971 Convention on Psychotropic Substances. The first treaty has 
been extremely influential in standardizing national drug control laws. The Controlled Substances 
Act was intended to fulfill our treaty obligations”).   
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passage of the first medical marijuana laws in California, there has been a steady 
push toward greater state acceptance of medical marijuana and a broadening of 
acceptance toward full legalization.  
As early as 2011, the INCB was commenting on the passage of state 
marijuana reforms in the United States. In its 2011 annual report, the INCB 
formally requested that the U.S. government “ensure the implementation of all 
control measures for the cannabis plant and cannabis, as required by the 1961 
Convention as amended by the 1971 Protocol, in all states and territories falling 
within its legislative authority.”127 Following the 2012 votes in Colorado and 
Washington, the INCB’s then-president, Raymond Yans, warned that the United 
States permitting recreational use of marijuana “would be a violation of 
international law, namely the United Nations Single Convention on Narcotic 
Drugs of 1961, to which the United States is a party.”128  
In September of 2014, President Obama made a statement supporting the 
United Nations drug conventions and the INCB, while at the same time asserting 
the right for nations to exercise flexibility in the application of laws conforming to 
those conventions. He stated,  
The United States shares the view of most countries that the U.N. 
drug conventions—without negotiation or amendment—are resilient 
enough to unify countries that often hold divergent views of the 
causes of the international narcotics problem, while at the same 
time providing a framework upon which to build the best solutions 
to it. The U.N. drug conventions, which recognize that the 
suppression of international drug trafficking demands urgent 
attention and the highest priority, allow sovereign nations the 
flexibility to develop and adapt new policies and programs in 
keeping with their own national circumstances while retaining their 
focus on achieving the conventions’ aim of ensuring the availability 
of controlled substances for medical and scientific purposes, 
preventing abuse and addiction, and suppressing drug trafficking 
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and related criminal activities. The United States supports the view 
of most countries that revising the U.N. drug conventions is not a 
prerequisite to advancing the common and shared responsibility of 
international cooperation designed to enhance the positive goals 
we have set to counter illegal drugs and crime.129 
If compliance of a signatory nation is questioned, the INCB may elect to 
exercise their rights under a specific rule. As stated in the board’s description of 
non-compliance authority, “Article 14 of the 1961 Convention can be used when 
the board believes that the aims of the 1961 Convention are seriously 
endangered by the failure of a state to comply with treaty obligations.” Under 
Article 14 (as quoted here):130 
• The board can start consultations and request explanations from
the government concerned.
• It can call upon the government concerned to adopt remedial
measures.
• It may propose that a study be carried out regarding a state’s drug
control problems.
• If the government has not given satisfactory explanations or
adopted remedial measures, the board may bring the matter to the
attention of the United Nations Economic and Social Council and
the Commission on Narcotic Drugs.131
The United States is not alone in this dilemma between international 
conventions and public sentiment toward decriminalization of marijuana. The 
Dutch have struggled with the issue since before California introduced the 
Compassionate Use Act. The problem that the Netherlands has experienced is 
one of regulation. In their debate over marijuana legalization, the Dutch are two 
decades ahead of us and provide a fair roadmap that we may follow if we choose 
129 “Presidential Determination—Major Drug Transit or Major Illicit Drug Producing Countries 
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to look where they have traveled. Since 1976, the Dutch Ministry of Justice has 
applied what is called a gedoogbeleid, or a policy of tolerance. Though the 
medicinal value of marijuana is one that is cited as justification for 
decriminalization, there is little in Dutch policy of tolerance with regard to 
potency. The Dutch do acknowledge a point in THC level at which marijuana, as 
a “soft drug,” loses its medicinal value in favor of psychoactive effect and hence 
becomes what the Dutch refer to as a “hard drug.” Since 2011, this has been 
enforced at levels of THC over 15 percent.132 
Since January 2015, the Dutch government has rethought its stance on 
marijuana tolerance and its classification as a soft drug for the purposes of 
enforcement. The policy of tolerance is giving way to much less open acceptance 
of the sale and use of marijuana. Described by the residents and mayor of one 
border city in the Netherlands, pot tourists who crossed the border made a 
nuisance of themselves by snarling traffic, littering, and even urinating in 
public.133 These problems have led the central government of the Netherlands to 
limit the number of marijuana coffee shops in the country, as well as shutter 
those that are too close to schools and outlaw the sale of marijuana products to 
those that are not citizens of the Netherlands.134 In line with the legacy Dutch 
model of lax enforcement, however, the Dutch central government is leaving 
implementation of these new measures to the local authorities. The New York 
Times quoted Dutch Justice Minister Io Opstelten as saying, “the best way of 
seeing which measures are effective is at the local level.”135 
It also appears from arrest and prosecution statistics that the enforcement 
of the laws regarding cultivation and importation are being applied with greater 
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force in the Netherlands as of late.136 The absence of a regulated production 
piece in the Dutch model has left what is commonly referred to as a “backdoor” to 
organized criminal activity by forcing the marijuana coffee shop owners to buy 
product from criminal syndicates.137 
As Figure 5 illustrates, as of June 2015, the worldwide trend is toward 
something other than marijuana prohibition.  
Figure 5.  Map of Legality of Cannabis138  
 
While countless countries are rethinking and modifying their laws with 
regard to marijuana, none appear to have gone as far as Portugal. According to 
an article in Time, in 2001, “Portugal became the first country in Europe to 
abolish all criminal penalties for personal possession of drugs.”139 The 
Portuguese stance toward drugs is one of public health and the treatment of 
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addiction rather than incarceration.140 The INCB hosts membership from 95 
percent of the countries in the world, and 185 signatory nations on the three 
counter-drug accords. Portugal is one of those nations. In reviewing the recent 
annual reports of the INCB, though the board acknowledges concern with the 
worldwide trend, it stops short of taking any substantive action against Portugal 
or any other countries pursuing marijuana decriminalization. It is noted in its 
annual report that the only nation as of 2015 under sanctions of Article 14 of the 
1961 Convention is Afghanistan.141 The board appears committed to working 
with the nations of the world as the evolution of drug policy plays out. 
C. LEGALITY: DOMESTIC 
Referenced here and attached in the appendix are tables defining the U.S. 
states’ positions on marijuana law as of November 9, 2016. A total of 28 states, 
the District of Columbia, and Guam have passed “comprehensive public medical 
marijuana and cannabis programs,”142 and an additional 17 states that allow the 
use of “low-THC” marijuana products in limited situations. To be included as 
having a comprehensive program, which Colorado, Washington, and the latest 
additions do, the National Conference of State Legislatures (as quoted here) 
requires the state’s legislation to contain the following:143 
1. Protection from criminal penalties for using marijuana for medical 
purposes; 
2. Access to marijuana through home cultivation, dispensaries, or 
other system that is likely to be implemented; 
3. It must allow a variety of marijuana strains; and 
4. It must allow either smoking or vaporization of some kind of 
marijuana product.144 
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These movements bring the total to 45 out of 50 as the number of states 
in the United States that have passed laws that are in direct conflict with Title 21 
of the U.S. Code, the Controlled Substance Act. Per §801, Congress makes the 
following findings with regard to the drugs listed in Schedules I–V, including 
marijuana:145  
(1) Many of the drugs included within this subchapter have a 
useful and legitimate medical purpose and are necessary to 
maintain the health and general welfare of the American 
people. 
(2) The illegal importation, manufacture, distribution, and 
possession and improper use of controlled substances have 
a substantial and detrimental effect on the health and 
general welfare of the American people. 
(3) A major portion of the traffic in controlled substances flows 
through interstate and foreign commerce. Incidents of the 
traffic, which are not an integral part of the interstate or 
foreign flow, such as manufacture, local distribution, and 
possession, nonetheless have a substantial and direct effect 
upon interstate commerce because— 
(A) after manufacture, many controlled substances are 
transported in interstate commerce, 
(B) controlled substances distributed locally usually have 
been transported in interstate commerce immediately 
before their distribution, and 
(C) controlled substances possessed commonly flow 
through interstate commerce immediately prior to 
such possession. 
(4) Local distribution and possession of controlled substances 
contribute to swelling the interstate traffic in such 
substances. 
(5) Controlled substances manufactured and distributed 
intrastate cannot be differentiated from controlled 
substances manufactured and distributed interstate. Thus, it 
is not feasible to distinguish, in terms of controls, between 
controlled substances manufactured and distributed 
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interstate and controlled substances manufactured and 
distributed intrastate. 
(6) Federal control of the intrastate incidents of the traffic in 
controlled substances is essential to the effective control of 
the interstate incidents of such traffic. 
(7) The United States is a party to the Single Convention on 
Narcotic Drugs, 1961, and other international conventions 
designed to establish effective control over international and 
domestic traffic in controlled substances.146 
Contained in the Controlled Substance Act are five options for the 
scheduling of dangerous drugs.147 The designation given to marijuana affects 
not only the recognition given its medical utility by the federal government, but 
also affects the research that can legally be done. To date, the Drug 
Enforcement Administration has only issued a single license for the cultivation of 
marijuana for research and that is to the University of Mississippi.148 The 
program, which is funded by NIDA, provides marijuana for research, but it is 
limited in its ability to produce various strains and potencies.  
In response to demand from the research community, NIDA currently 
offers marijuana cigarettes in varying potencies, up to 6.7 percent THC and bulk 
marijuana in strains up to 12.4 percent THC.149 The process by which these 
samples are obtained is an arduous one. Dr. Sue Sisley, a psychiatry professor 
and post-traumatic stress disorder researcher at the University of Arizona, 
recently received approval to use marijuana in her studies.150 The approval 
process, as described in the Washington Post article about Dr. Sisley’s struggle, 
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involved first applying to the U.S. Department of Health and Human Services to 
purchase marijuana from the program at the University of Mississippi. Then she 
obtained approvals to use the marijuana in human trials from the Food and Drug 
Administration. Finally, the DEA had to approve the possession and 
transportation of the drug.151  
In the 1997 book he co-authored with James Bakalar, Harvard psychiatrist 
Lester Grinspoon argues that marijuana’s Schedule I status has impeded 
research. “Since 1970,” he says, “it has been the major reason why the kinds of 
large double-blind studies which have been the basis for FDA approval of 
medicines since the mid-1960s have been impossible to pursue in this 
country.”152 Moving marijuana from Schedule I to II or III may allow for greater 
research of the drug’s medical benefit and health risks. It should also be noted 
that moving marijuana to Schedule III might also eliminate the Internal Revenue 
Service section prohibitions on the movement of proceeds and taking of business 
deductions with regard to profits and expenses related to “trafficking in controlled 
substances” as listed in Schedules I and II.153 
1. Impact on Law Enforcement
Through continued member participation on the INCB, the U.S. federal 
government appears to remain committed to the United Nations’ mandates for 
“shared responsibility to drug control efforts in areas such as demand reduction, 
supply reduction, judicial cooperation, and the control of illicit trade in drugs.”154 
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At the same time, the United States is home to a federal system of government, 
a system in which individual states enjoy a certain amount of freedom in ensuring 
their constituents common welfare (see Figure 6).  
Figure 6. Concentric Circles of Federalism155 
In the United States, 45 states and the District of Columbia have seen 
their way to establishing laws with regard to the production, possession, and use 
of medical marijuana. In the cases of Colorado and Washington, and now five 
others, those efforts have included the legalization of marijuana for recreational 
purposes. 
In 2013, the federal government answered the state decriminalization and 
legalization efforts with a memo from the DOJ.156 In the August 2013 memo and 
again reiterated in a February 2014 memo, Deputy Attorney General James M. 
155 David J. Shestokas, “American Federalism: Source, Purpose, and Establishment Part II,” 




Cole lays out guidelines for the federal enforcement and prosecution of violations 
of Title 21 marijuana laws.  
Specifically, the Cole memo enforcement priorities are:157 
1. Preventing the distribution of marijuana to minors
2. Preventing revenue from the sale of marijuana from going to
criminal enterprises, gangs, and cartels
3. Preventing the diversion of marijuana from states where it is legal
under state law in some form to other states
4. Preventing state-authorized marijuana activity from being used as a
cover or pretext for the trafficking of other illegal drugs or other
illegal activity
5. Preventing violence and the use of firearms in the cultivation and
distribution of marijuana
6. Preventing drugged driving and the exacerbation of other adverse
public health consequences associated with marijuana use
7. Preventing the growing of marijuana on public lands and the
attendant public safety and environmental dangers posed by
marijuana production on public lands
8. Preventing marijuana possession or use on federal property158
Another piece of federal guidance came recently in the form of an 
amendment to Senate appropriations bill H.R. 4660. On June 11, 2015, the U.S. 
Senate Appropriations Committee passed a rider, authored by California 
Representatives Dana Rohrbacher, a Republican, and Sam Farr, a Democrat, to 
the appropriations bill. The rider simply states at the end of the bill that 
none of the funds made available in this act to the Department of 
Justice may be used, with respect to any of the States of Alabama, 
Alaska, Arizona, California, Colorado, Connecticut, Delaware, 
Florida, Georgia, Hawaii, Illinois, Iowa, Kentucky, Louisiana, Maine, 
Maryland, Massachusetts, Michigan, Minnesota, Mississippi, 
Missouri, Montana, Nevada, New Hampshire, New Jersey, New 
Mexico, New York, North Carolina, Oklahoma, Oregon, Rhode 
Island, South Carolina, Tennessee, Texas, Utah, Vermont, Virginia, 
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Washington, and Wisconsin or with respect to either the District of 
Columbia or Guam, to prevent any of them from implementing their 
own laws that authorize the use, distribution, possession, or 
cultivation of medical marijuana.159 
After the House vote and in anticipation of the Senate voting, 
Representative Farr stated the following regarding the intent of the rider: 
States with medical marijuana laws are no longer the outliers; they 
are the majority. This vote shows that Congress is ready to rethink 
how we treat medical marijuana patients in this country. This 
amendment gives states the right to determine their own laws for 
medical marijuana use; free of federal intervention. It also gives 
patients comfort in knowing they will have safe access to the 
medical care legal in their state without the fear of federal 
prosecution. But while momentum is on our side, there is still work 
to be done to get this bill out of the Senate. In the meantime, the 
federal government can continue to prosecute medical marijuana 
patients. This is more than just a waste of taxpayer dollars; it 
needlessly destroys lives and tears families apart. The majority of 
states and now the House of Representatives have clearly stated 
that this absurd policy needs to stop. I look forward to working with 
my colleagues in the Senate to pass this amendment and remove 
the burden weighing down so many patients in our country.160 
With regard to state, local, and tribal enforcement of marijuana laws, there is no 
longer the overlapping prohibition of marijuana that existed prior to 1996. As 
listed in the appendix there are myriad new laws on the books across the 
country. Across 45 states, there are law enforcement personnel allowing 
marijuana activities that are within the laws of their respective jurisdictions, but 
remain in conflict with the federal statute. 
A coalition of chiefs of police from around the country make up an 
organization known as the Major Cities Chiefs Association (MCCA). In June of 
2014, the MCCA published a position paper on marijuana decriminalization. The 
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body focused on medical marijuana, opposing the legalization of marijuana, but 
giving a six-point position on the decriminalization for medical purposes:  
1. Support for more scientific research on the risks of marijuana use 
before further legislative action is taken or medical use is 
expanded.  
2. Support stronger regulations and processes to prevent abuse and 
fraud involving “medical marijuana.”  
3. Support penalties for driving while impaired by alcohol and 
marijuana at the same time.  
4. Support legislation giving law enforcement the ability to detect and 
test drivers for impairment by marijuana. Establish thresholds for 
impairment.  
5. Oppose legalization of marijuana. Recognize the need for lesser 
penalties for possession of small amounts.  
6. Oppose the use or consumption of marijuana in public, anytime, 
anywhere.161  
In its position paper, the MCCA, claiming a “frontline” view of the impact of 
drugs, states, “there is a direct nexus between crime and drug abuse, which 
affects the safety of our communities.”162 Researchers at the University of Texas 
sought to examine whether or not there is a connection between what they call 
“medical marijuana legalization (MML)”163 and criminal behavior. Published in 
March of 2014, the article sought to do several things, as stated in the 
introduction: 
The issue addressed in this article is whether MML has the effect of 
increasing crime. While there are many mechanisms by which MML 
might affect crime rates, the most obvious is by increasing the 
number of marijuana users, which may lead to a broader social 
acceptance of drug using behaviors and drug users. To the extent 
that marijuana use serves as a “gateway” to harder drugs such as 
cocaine and heroin, MML could lead to long-term increases in 
crime as an ever-growing number of illicit drug users engage in 
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serious predatory crimes to support their habits. But even if MML 
does not lead to a rise in marijuana use (especially among youth), 
the laws could still stimulate crime as newly opened medical 
marijuana dispensaries provide criminals with a highly attractive 
target with their repository of high quality marijuana and customers 
carrying large amounts of cash.164 
The University of Texas researchers collected crime data for all 50 states 
from the DOJ covering the 17-year period from 1990 to 2006. They then 
compiled all Part I crime statistics—homicide, rape, robbery, assault, burglary, 
larceny, and auto theft—for each. The researchers then compared the changes 
in mean crime levels for all 50 states with those in 11 states that passed some 
form of MLL legislation.165 The following seven graphs (see Figure 7) show the 
data for each of the Part I crime categories illustrating the rates in non-MML 
states compared with those states that have MLL in place.  
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Figure 7. Mean State Crime Rates as a Function of Year166 
166 Source: Ibid.  
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Table 1 “reveals the impact of the MML trend variable on crime rates, 
while controlling for the other time-varying explanatory variables.”167 The 
headings represent each of the Part I crime categories. The variables, including 
MML, are listed on the left. The numbers represent either the increase or 
decrease in each of the respective reported crime totals.  
Table 1.   The Effect of Medical Marijuana Laws on Crime: Evidence from 
State Panel Data, 1990–2006168 
167 Ibid.  
168 Source: Major Cities Chiefs Association, “The Effect of Medical Marijuana Laws.” 
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As stated in University of Texas researchers’ conclusion, two findings 
worth noting emerged from their analysis.169 First, the impact of MML was 
negative or lacked statistical significance in all but two of the models, which could 
actually indicate a “dampening effect”170 on those crimes. The second key 
finding was that the only findings that were statistically significant were those in 
the models that related to homicide and assault.171 The results “indicated 
approximately a 2.4 percent reduction in homicide and assault, respectively, for 
the each year the MML was in effect.”172 
As the study admits, there are many factors confounding a study that 
looks at only one factor’s effect on crime rate; however, there was no glaring 
evidence that the legalization of marijuana in states that have done so have seen 
any increase in the listed crime totals. In fact, collectively, the states with 
legalized marijuana enjoyed a decrease in most violent crime for each year their 
medical marijuana laws have been in effect.173 
2. Medical Impact
NIDA reports that the “U.S. Food and Drug Administration (FDA) has not 
recognized or approved the plant marijuana as a medicine.”174 In a 1998 article 
by Jonas, he explains, “A major criticism of alternative therapies like medical 
marijuana is they have not been scientifically tested, leading many to question 
their safety and efficacy.”175 As discussed earlier, the stifling process by which 
marijuana is approved and obtained for research is one of the biggest hurdles in 
169 Major Cities Chiefs Association, “The Effect of Medical Marijuana Laws.” 
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the understanding of its effects. The debate on the subject of the efficacies of 
marijuana rages, and its discussion in medical circles has gone on for ages. 
However, due to legal restrictions, the research supporting the various positions 
is not anywhere near as robust as the argument.  
In April of 2014, researchers for the American Academy of Neurology 
“published a systematic review of medical marijuana (1948–November 2013) to 
address treatment of symptoms of multiple sclerosis (MS), epilepsy, and 
movement disorders.”176 In the article by Koppel et al., they explain that that 
“graded the studies according to the American Academy of Neurology 
classification scheme for therapeutic articles.”177 The team was able to find only 
34 research studies that rated inclusion.178 The findings of the study showed that 
oral cannabis extract and THC were “probably effective” in the treatment of 
spasticity, painful spasms, urinary dysfunction, and tremors, as they were tested 
in patients suffering from multiple sclerosis.179 The researchers “reviewing the 
scientific literature on marijuana found only 1729 studies in the literature.”180 Of 
those, only the 34 studies noted in their work “met the criteria to be useful in their 
analysis of the efficacy of medical marijuana on neurological conditions.”181  
Dr. Fields is the Chief of the Nervous System Development and Plasticity 
Section of the National Institutes of Health, in Bethesda Maryland. In his posting 
on brainfacts.org entitled “The Absurdity of Medical Marijuana,” Douglas Fields 
points out several correlations to a lack of studies of marijuana in the field of 
neurological research.182 He finds that while only  
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34 studies were found for the enormous range of neurological 
conditions where activation of CB1 and CB2 receptors in the brain 
by compounds in marijuana could have an effect, there are 32,836 
studies in the scientific literature on health and tobacco.183  
There are 87,735 studies on “‘health and alcohol’ in the medical literature 
(PubMed search).”184 The primary difference between the substances studied is 
their availability. Tobacco and alcohol are legal and readily available for research 
purchases; marijuana is not. 
As of January, 2014, there were 28 active NIDA grants related to the topic 
of marijuana and the benefits of individual cannabinoid chemicals from the 
marijuana plant for medical purposes.185 The current federally funded research 
is in six different disease categories: autoimmune diseases, inflammation, pain, 
psychiatric disorders, seizures, and substance abuse.186 In addition to the NIDA-
funded studies, there have been 16 independently funded studies since 1999 
exploring the potential medical benefits of marijuana.187 
Prior to discussing the potential medicinal benefits of marijuana and 
related studies, it is important to understand how marijuana affects the brain. The 
cannabinoid (CB) receptors within the brain have been identified as the sites 
where the chemical components contained in marijuana, including THC, bind and 
cause various psychoactive effects.188 These CB receptors, combined with the 
body’s naturally occurring chemicals, anandamide and 2-arachidonoyl glycerol, 
comprise the endocannabinoid system189 (see Figure 8).  
183 Ibid.  
184 Ibid.  
185 National Institute on Drug Abuse, “NIDA Research on the Therapeutic Benefits of 
Cannabis and Cannabinoids,” last updated May 2015, http://www.drugabuse.gov/drugs-abuse/
marijuana/nida-research-therapeutic-benefits-cannabis-cannabinoids.  
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Figure 8.  The Endocannabinoid System190 
 
As illustrated in Figure 8, the effect that THC and other cannabinoids have 
on the brain is dependent on what part of the brain the affected CB receptors are 
located in. The illustration in Figure 9 shows nine structures of the brain that 
contain high numbers of CB receptors, and the manner in which THC affects 
each respective structure.  
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Figure 9. CB Receptors in the Brain and THC Effects191 
In January 1997, the White House Office of National Drug Control Policy 
(ONDCP) asked the Institute of Medicine (IOM) to “conduct a review of the 
available scientific evidence to assess the potential health benefits and risks of 
marijuana and its various cannabinoids.”192 The results of this study were 
published in the 1999 book Marijuana and Medicine: Assessment of the Science 
Base by Joy et al. Prior to 1999, the most recent report was published by the 
IOM in 1982. This earlier work was produced prior to the findings in the 1980s 
and 1990s with regard to discovery of the CB receptors and their function in the 
brain.193  
191 Source: Ibid.  
192 Joy, Watson, Jr., and Benson, Jr., Marijuana and Medicine, 1. 
193 Ibid., 2.  
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After much research, the IOM made several general conclusions, as 
stated in the executive summary of the 1999 book: 
1. Cannabinoids likely have a natural role in pain modulation, control 
of movement, and memory. 
2. The natural role of cannabinoids in immune systems is likely multi-
faceted and remains unclear. 
3. The brain develops tolerance to cannabinoids. 
4. Animal research demonstrates the potential for dependence, but 
this potential is observed under a narrower range of conditions than 
with benzodiazepines, opiates, cocaine, or nicotine. 
5. Withdrawal symptoms can be observed in animals but appear to be 
mild compared to opiates or benzodiazepines, such as diazepam 
(Valium).194 
With regard to the efficacy of cannabinoid drugs, the authors of Marijuana 
and Medicine state that the accumulated data indicate a potential therapeutic 
value, especially for indications such as pain relief, control of nausea and 
vomiting, and appetite stimulation.195 They note that the best established 
therapeutic effects are from THC. THC and cannabidiol (CB) are the two most 
prevalent cannabinoids in marijuana.196  
Joy et al. reviewed reports detailing over 30 purported medical uses of 
marijuana. They narrowed the scope of their research to five areas of symptoms 
and conditions. These areas were pain, nausea and vomiting, wasting syndrome 
and appetite stimulation, neurological symptoms including muscle spasticity, and 
glaucoma.197 While the report warns repeatedly of the dangers associated with 
smoked marijuana, they acknowledge that the scientific data indicate a medicinal 
value to marijuana, in spite of the risks.198 Furthermore, the researchers make 
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the recommendation to continue clinical trials of cannabinoid drugs so as to 
develop safer, reliable, more rapid-onset systems of delivery.199  
When analyzing the potential consequences of marijuana use, the 
researchers for the 1999 study compiled data from four studies relating to the 
psychoactive effects of THC and the point at which a patient reported “feeling 
high.”200 The highest concentration of marijuana cigarette smoked by any of the 
subjects in the studies was 3.5 percent THC.201 Due to the inherent dangers and 
the already discussed lack of testing material, there is still no similar research at 
higher levels of THC concentration.202 The samples used in trials focused on the 
efficacies of marijuana were all below this level. 
Future studies are needed to explore the testing of marijuana in its many 
compositions for medical purposes. These studies must be controlled clinical 
examinations of marijuana in its natural and synthetic forms and the various 
methods of ingestion. Today, smoked marijuana is not the only form of marijuana 
in use. According to a 1998 article by Calhoun, Galloway, and Smith, “There are 
a number of forms of marijuana that are used for medical purposes, including a 
synthetic form, Marinol (dronabinol), which is taken orally.”203 According to 
Calhoun, Galloway, and Smith,  
Marinol is a Schedule III prescription drug, approved by the FDA in 
1985 for treatment of nausea and vomiting of cancer chemotherapy 
patients who have not responded to conventional antiemetic 
therapy. In 1992, the FDA also approved it for use in loss of 
appetite and weight loss related to AIDS.204  
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Another form used in Canada is a spray alternative called Sativex.205 In 2006, 
the FDA issued an investigational new drug application for Sativex.206 
If marijuana were moved from Schedule I to either Schedule II or III, it is 
possible that the DEA would be far more likely to grant licenses for the cultivation 
of the substance for research. Currently, the University of Mississippi holds the 
exclusive right to produce such material and supplies marijuana cigarettes with 
no more than 6.7 percent THC.207 With an increase in availability of plant 
material, as well as greater acceptance of the research in the form of increased 
grant funding, there would be much more scientific data available with regard to 
the efficacies of marijuana and its components. 
3. Health and Public Safety 
The Substance Abuse and Mental Health Services Administration 
(SAMHSA) is the agency within the U.S. Department of Health and Human 
Services that “leads public health efforts to advance the behavioral health of the 
nation.”208 SAMHSA’s stated mission is “to reduce the impact of substance 
abuse and mental illness on America’s communities.”209 SAMHSA administers 
the National Survey on Drug Use and Health (NSDUH), which is a “primary 
source of statistical information on the use of illegal drugs, alcohol, and tobacco 
by the U.S. civilian, noninstitutionalized population aged 12 or older.”210 
Conducted on behalf of the U.S. federal government since 1971, the survey 
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currently “collects data through face-to-face interviews with a representative 
sample of the population at the respondent’s place of residence.”211 Results, 
such as those in Figure 10 for past month use in 2013, are published for 
responses to questions pertaining to each of the drug types/categories.  
Figure 10. Past-Month Illicit Drug Use among Persons 
Aged 12 or Older: 2013212 
According to the data compiled by the NSDUH, in 2011, over 18 million 
people, age 12 and older, report past-month use of marijuana.213 In 2013, the 
number rose to 19.8 million (see Figure 11). Though this number represents less 
than 10 percent of the total population, and 58 percent of people report that they 
211 Ibid. 
212 Source: Center for Behavioral Health Statistics and Quality, Results from the 2013 
National Survey on Drug Use and Health: Summary of National Findings (Rockville, MD: 
Substance Abuse and Mental Health Services Administration, 2013), http://www.samhsa.gov/
data/sites/default/files/NSDUHresultsPDFWHTML2013/Web/NSDUHresults2013.pdf.  
213 Center for Behavioral Health Statistics and Quality, Results from the 2011 National 
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and Mental Health Services Administration, 2011), http://media.samhsa.gov/data/NSDUH/
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have never used marijuana, the trend is clear. A look at Figure 11 illustrates the 
fact that illicit drug use is on the rise and that marijuana accounts for much of the 
increase. 
Figure 11.  Past-Month Use of Selected Illicit Drugs among  
Persons Aged 12 or Older: 2002–2013214 
 
The news is not all bad, however. Greater medical accessibility to the drug 
may account for some of the increase, and the increase in past-month use was 
not in any of the age groups under 21 years of age.215 In fact, every age bracket 
from age 12 through age 20 reported a decrease in the use of illicit drugs over 
the last year (see Figure 12). SAMHSA reported that past-month use of 
marijuana by youth ages 12–17 accounted for 7.5 percent of illicit drug use in 
2013. This is down from 7.9 percent in 2011.216 
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Figure 12. Past-Month Illicit Drug Use by Age among Persons 
Age 12–65+: 2012–2013217 
While the country as a whole saw a decrease in youth past-month use of 
marijuana, the state of Colorado saw different statistics. Colorado voted to 
legalize marijuana for recreational use in 2009. When comparing the three years 
prior to 2009, with the three years after, there was a 25 percent increase in the 
past-month use of marijuana by 12–17 year-olds (see Figure 13).218 When 
comparing the responses of 12–17 year-olds nationwide, the results show that 
the top 10 states in past-month marijuana use all have laws allowing marijuana 
use for medical or recreational purposes. The bottom 10 states still prohibit the 
use of marijuana by law (see Figure 14). The national average of 7.5 percent of 
12–17 year-olds reporting past-month drug use contrasts starkly with those in 
Colorado, with nearly 10.5 percent admitting marijuana use in the past month 
(see Figure 15). 
217 Source: Ibid.  
218 Rocky Mountain High Intensity Drug Trafficking Area, The Legalization of Marijuana in 




Figure 13. Average Past-Month Use of Marijuana among Persons Ages 12–
17: Pre- and Post-medical Marijuana Commercialization Year 2009219 
219 Source: Rocky Mountain High Intensity Drug Trafficking Area, The Legalization of 
Marijuana.   
 59 
Figure 14.  Past-Month Usage of Marijuana among Ages 12–17 in Medical 
Marijuana States in 2012220 
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Figure 15.  Past-Month Marijuana Use among Ages 12–17,  
National versus Colorado: 2006–2012221 
 
Regarding the increased use of marijuana in young people (ages 12–17), 
it is important to point out that any adverse effects of the drug are far worse when 
acting on a still-developing brain and body.222 It should also be pointed out that 
risks are quantified in terms merely of reported use, with no factor for THC 
content. The inconsistent and ever-increasing THC levels seen in marijuana, as 
of late, increase all of these risk factors.  
Another inherent risk of marijuana use is one already discussed—that of 
impaired driving. Studies show that drivers testing positive for marijuana or who 
report driving “within three hours of marijuana use are twice as likely to be 
involved in a traffic collision.”223 Another illustration of the increased adverse 
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health effects of marijuana legalization are emergency department visits before 
and after efforts to legalize the recreational use of marijuana. According to the 
SAMHSA Drug Abuse Warning Network Report, dated February 2013, 
emergency department visits involving illicit drugs were relatively stable from 
2004 (991,640 visits) to 2009 (974,392 visits).224 2009 is the year that Colorado 
became the first state to allow recreational use of marijuana.225 Between 2009 
and 2011, emergency department visits attributable to marijuana abuse rose by 
19 percent.226 Again, there is no data with regard to THC levels of the marijuana 
that is causing the increase in emergency department visits, but we do have the 
report from the Colorado Department of Public Health that states that typical THC 
levels in that state are in the 20 percent range.227 
In spite of reports that show fewer adolescents believe that “regular 
cannabis use is harmful to their health,”228 another recent study concludes that 
there is “sufficient evidence to warn young people that using cannabis could 
increase their risk of developing a psychotic illness later in life.”229 Yet another 
research study polled regular users of smoked marijuana. When asked to rate 
the “subjective effects of cannabis on their cognition, memory, career, social life, 
physical health and mental health, large majorities of heavy users (66–90 
percent) reported a negative effect.”230 
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D. CHAPTER CONCLUSION 
In conclusion, there has been evidence provided that current federal law 
and policy is creating conflict in all four of the areas explored in this thesis: legal, 
law enforcement, medical, and health and public safety. Recent and continuing 
changes in state marijuana laws are in direct conflict with current federal 
marijuana scheduling and the mandates set forth in international accords to 
which the United States is a party. Current scheduling stifles the very research 
that would tend to provide evidence for the need to reschedule marijuana in the 
first place. Similarly, current scheduling precludes the classification of marijuana 
as a prescription drug, which would provide for its regulation and compliance with 
federal and international law. 
Evidence has been shown of the medicinal value of marijuana, and also 
the dangers associated with its use early in life, impaired driving, and unknown 
THC content. While decriminalization appears to lead to greater use, even by 
those not legally authorized, there has been no evidence that increased 
marijuana use leads to increase in Part-I (serious) reported criminal activity. The 
ambiguity in federal enforcement and the increasing tolerance by states and 
municipalities have started us down the road to rescheduling marijuana and 
THC. Now, we need to finish the trip. 
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III. ALTERNATIVES: OPTIONS FOR POLICY GUIDANCE 
So far in this thesis, the author has identified a host of reasons why 
current federal marijuana policy is not sustainable: the myriad conflicts that arise 
between the evolving state marijuana legal landscape and the federal statutory 
prohibition on marijuana include the continued non-compliance with international 
accords, inconsistent law enforcement and prosecutorial guidance; a lack of 
research, increased use among developing teens and young adults, and an 
inability for those profiting to legally use the banking system. This section 
discusses three options for federal policy. 
A. OPTION ONE: STATUS QUO 
The first option is to continue with the status quo—to continue business as 
usual. As has already been quoted from Bardach, this policy option is not to say 
that the federal government has the option to “do nothing,” but rather to continue 
the trend that is already underway. This trend, as evidenced by the guidance put 
forth in the Cole memo,231 is one of relaxed enforcement. In this option, the 
states would continue to enact their own marijuana legislation with no regard for 
the standing federal statutes and little regard for the regulation of marijuana 
production, sales, and use. The federal government would continue to allow such 
state legislative freedom, while continuing relaxed enforcement of the current 
federal marijuana laws. 
B. OPTION TWO: STRICT ENFORCEMENT 
A second option, arguably at the other extreme, would be for the federal 
government to assert its supremacy over the states with regard to marijuana 
legislation. In this scenario, marijuana would remain in Schedule I of the 
Controlled Substance Act and illegal under federal statute. The guidance under 
the Cole memo, and the legislative mandates for federal non-interference in state 
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marijuana lawmaking would be rescinded. Federal marijuana laws would be 
enforced as written. The biggest hurdle with implementation of this option would 
likely be state compliance.  
C. OPTION THREE: RESCHEDULING 
A hybrid option would be to reschedule marijuana and then mandate 
compliance with federal laws by all states and territories. This “middle-of-the-
road” approach would begin with the moving of marijuana from Schedule I of the 
Controlled Substance Act to Schedule III. Rescheduling would allow marijuana to 
be prescribed and fall under the purview of all of the existing laws that govern the 
production, distribution, and use of prescription drugs, including their availability 
for more robust research.  
D. CRITERIA: WHAT DOES AN EFFECTIVE POLICY LOOK LIKE? 
An effective federal policy on marijuana legislation is one that addresses 
the conflicts that have been evidenced with regard to the four criteria explored 
through the research: legality, impact on law enforcement, medical impact, and 
marijuana’s health and safety risk. Effective federal policy is not one that states 
one thing statutorily and is executed in quite another in terms of enforcement and 
prosecutorial guidance. Rather, an effective policy is one that can be enforced 
the way that it is written. 
As stated in the methodology, when defining the problems and exploring 
alternatives, we should first think in terms of deficit or excess. The research has 
clearly shown both. The purpose of proposing change to the existing federal 
marijuana strategy is to fill the void in effective enforcement guidance. A sound 
option is one that, to the extent possible, aligns with the desires of the states that 
have voted for change, as well as with the statutory compliance requirements 
that we share with the international community. It is one that balances personal 
freedom with the federal government’s responsibility to ensure public safety. By 
stressing medical use over recreational use, regulation over euphoria, and safety 
over freedom, there is a way to responsible change policy.  
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The literature review has also identified a deficit in marijuana research. 
The current federal marijuana prohibitions have a negative effect on the research 
that is needed to effectively further this discussion and to frame an effective 
policy. An effective federal policy is one that acknowledges the potentially 
positive medical impact that marijuana could have and allows for its robust 
clinical testing.  
As for excess, we need only look to the states that have gone beyond 
medicinal use and into allowing the use of unregulated THC content for 
recreational purposes. The federal government has a public safety responsibility 
to inform the public of the proven risks of abusing marijuana and implement 
policies that mitigate those risks. There is evidence of the need for change in the 
sheer number of states that have opted to enact laws contrary to the federal 
policy; 45 out of 50 states now have marijuana laws that are in direct conflict with 
the current federal laws. 
Lastly, effective policy would once and for all define nationally what 
“medicinal marijuana” is. As previously stated, very few of the states that have 
medicinal marijuana laws take the extra step of defining it terms of THC and CBD 
content. There are other drugs of abuse in categories of the Controlled 
Substance Act other than Schedule I. An effective policy is one that concedes 
that marijuana should join those listed elsewhere that are defined, regulated, 
prescribed, researched, and used responsibly.  
E. CONSEQUENCES: PROJECTING OUTCOMES OF POLICY OPTIONS 
In this chapter, the author has presented three federal policy options along 
with the criteria for gauging the problems and assessing potential benefits. The 
following discussion is a projection of the options as they relate to those criteria. 
1. Option One: Status Quo (Legality) 
The status quo option would do nothing to resolve the conflicts between 
state and federal laws, nor would it move us any closer to compliance with the 
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INCB mandates. Relaxing the enforcement of the standing federal laws does not 
offer a long-term solution. In fact, continuing the policies that stifle research and 
promote state autonomy would lead to further lack of alignment between federal 
and state law. The country is reaching a point where every state will have 
enacted some form of legislation that conflicts with the federal scheduling of 
marijuana; only five have not done so at this point. Changes to state legislation 
does nothing to reconcile the conflict between local marijuana legality and the 
illegality of using the banking system to deposit and move proceeds. 
a. Impact on Law Enforcement 
With more states opting for decriminalization of marijuana, there is 
increased disparity between federal and local law enforcement directives. The 
Cole memo provides federal law enforcement personnel and prosecutors with 
guidance. As the number of states that have their own marijuana laws increases, 
so increases the number of states that will enjoy relaxed federal enforcement of 
the Title 21 laws.232 Relaxed enforcement does not change the laws as they are 
written, and therefore leaves them open to new and different interpretation with 
changes of administration or political will. 
b. Medical Impact 
As evidenced by the current trend, public perceives that marijuana does in 
fact have medicinal value. Research has been presented to support this notion, 
but there is also a need for further exploration into the subject. With no change in 
federal marijuana policy, the availability of marijuana for testing purposes and 
research funding will remain limited. 
c. Health and Public Safety Risk 
Of the states that have opted for decriminalization or legalization of 
marijuana, only a few have passed restrictions on the chemical composition of 
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the legalized substance. The status quo option, with its continued federal 
prohibition, does not offer the federal government any option for defining 
medicinal marijuana. Without these limits and regulations, states are free to allow 
the possession and use marijuana in potencies and compositions shown to pose 
a health and public safety risk. 
2. Option Two: Strict Enforcement (Legality) 
The legality option, with the assertion of current federal law over those 
enacted to their contrary by the states, would disenfranchise the voters in 90 
percent of the states in this country. The biggest hurdle to implementation of this 
option would likely be state compliance. In addition to the potential constitutional 
debate that would ensue, there would be the issue of how practically to reverse 
21 years of legislation. A path similar to that of the Minimum Drinking Age Act of 
1984 would likely need to be followed, tying states’ compliance with some 
significant federal funding. The Minimum Drinking Age Act (23 U.S.C. §158) 
requires that states prohibit “persons under 21 years of age from purchasing or 
publicly possessing alcoholic beverages” as a condition of receiving federal 
highway funds. Though this option would satisfy our legal requirements for 
compliance with the standing treaties, it would essentially end any debate on 
marijuana’s medical value. 
a. Impact on Law Enforcement 
This legality option may provide the clearest guidance to state and local 
law enforcement and prosecution personnel, but it would impose enforcement 
guidelines that are not realistic given the current climate. 
b. Medical Impact 
Strict enforcement of marijuana’s Schedule I classification in the 
Controlled Substance Act would indicate that the substance has no legitimate 
medical purpose. The findings of researchers that reviewed reports highlighting 
over 30 purported medical uses of marijuana yielded two main points. One, there 
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is scientific data to support a medical benefit to the use of marijuana and THC; 
two, researchers recommend clinical trials continue in order to develop safer and 
more consistent methods of delivery than smoking.233 This creates the first point 
of contention for the states and essentially the same fodder that led to the 
passage of Proposition 215, dating back to 1996 in California.  
c. Health and Public Safety Risk 
By continuing the federal prohibition on marijuana and mandating the 
same from the states, there would likely be a reduction in its use by those that 
have begun using the drug only since its legalization. This policy option, though 
intended to end the use of all marijuana, would have the effect of limiting the 
availability of medicinally beneficial marijuana in favor of black market marijuana 
that may increase the potential risks to the users. 
3. Option Three: Rescheduling (Legality) 
The moving of marijuana from Schedule I to Schedule III of the Controlled 
Substance Act would allow marijuana to be prescribed and to fall under the 
purview of all of the existing laws that govern the production, distribution, and use 
of prescription drugs. Along with the other INCB-listed dangerous drugs that are 
classified as Schedule III, marijuana would no longer be allowed for other than 
medical use and conform squarely with all of the international treaties to which 
the United States is party. To facilitate the repeal of state laws that allow for 
marijuana’s use recreationally, as mentioned above, the federal government 
would likely have to tie state compliance to some significant federal funding, such 
as that allocated for transportation projects. 
a. Impact on Law Enforcement 
Moving marijuana to Schedule III and giving states clear guidance as to its 
allowable uses would allow federal, state, local, and tribal law enforcement 
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entities to align their protocols and finally coordinate efforts. As a Schedule III 
substance, proceeds and profits associated with marijuana’s production and sale 
would no longer be subject to the prohibitions set forth in the Banking Secrecy 
Act for Schedule I drugs. This means these monies would no longer be 
precluded from entering and using the legitimate banking system. 
b. Medical Impact 
The research has shown that marijuana may be a dangerous drug worth 
banning. The research has also shown the potential for marijuana to provide 
medical relief to millions of individuals. If marijuana were a Schedule III 
substance, it would allow for this medical use and facilitate the defining and 
quantifying of “medicinal marijuana.” 
c. Health and Public Safety Risk 
Moving marijuana to Schedule III moves the debate from one centered on 
medical value to one around the issue of potency, consistency, and amount. 
Marijuana, as the whole plant, with all of its varied and increasingly more 
psychoactive strains, one could argue is not supposed to have been the subject 
of an informed discussion about scheduling or classification at all. Rather, as 
shown by the evidence, the discussion should instead focus on where to properly 
schedule THC in relationship to CBD and at what levels. If the goal of the 
Controlled Substance Schedule is to rate the likelihood of abuse, level of physical 
and psychological dependence, and medical value, then the proper subject of the 
schedule is narrowly defined “marijuana;” marijuana defined by the very things 
that affect those values, the THC and CBD content. As a Schedule III drug, 
another allowance for the production and use of marijuana is research. It is 
through the much needed research that we can answer the questions of potency 
and risk that affect health and public safety. 
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F. TRADE-OFFS: BUILDING POLITICALLY FEASIBLE OPTIONS 
The least politically feasible option would be for the federal government to 
leave the current federal laws in place and begin to vigorously enforce them. A 
more politically feasible, but ineffective policy choice, would be to continue the 
current relaxed enforcement and wait until something forces change. Since April 
of 2015, the country has been without an administrator appointed to the DEA. 
There is new presidential administration and with it comes an opportunity for 
leadership and policy change.  
To reschedule marijuana as a Schedule III substance would be a move 
that I believe would be seen as the federal government seeking to better align 
itself with the will of the states. Not only would it provide an opportunity for people 
to legally possess and use marijuana, but it would allow steps to ensure its safe 
use, as well as to further the research into its dangers and benefits.  
G. DECISIONS: MAKING POLICY RECOMMENDATIONS 
My advice to the new administration would be to look at the issue of 
marijuana legislation with a fresh eye as well as through the lens of all that we 
have learned over the last few years. With all that we have learned about 
marijuana and its components, and all that we are learning about the desires of 
the voting populous, we can move forward with policy recommendations are for 
the future. I believe the future requires the federal government to acknowledge 
that marijuana’s placement in Schedule I of the Controlled Substance Act was 
not meant to be permanent. The first federal policy recommendation for 
marijuana actually came with its initial classification. Dr. Egeberg, stated himself 
that “our recommendation is that marijuana be retained within Schedule I at least 
until the completion of certain studies now underway to resolve the issue.”234 
Though the research did not identify what these “studies currently underway” 
may have been, it can logically be asserted that they have not been ongoing 
since 1970.  
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The next appointed DEA administrator will be expected to make a decision 
on the subject, as will the newly-appointed attorney general. As described as part 
of the review of literature, the process by which marijuana can be moved from 
Schedule I to Schedule III is not a complicated one. The systems for regulating, 
approving, and producing THC and the other components of marijuana are 
already in place, as in the case of synthetic THC, which already has a place 
outside of Schedule I. 
On the question of state compliance, it is important for the federal 
government to work quickly to ensure access to marijuana as a legitimately 
prescribed drug. The key to popular acceptance is framing the new policy to 
closely resemble what the voters have voted in favor of that the states comply for 
their own political well-being. Remember that most of the 45 states, the District of 
Columbia, and Guam have passed laws allowing for the medicinal use of 
marijuana. That is precisely what marijuana as a Schedule III drug will provide, 
along with treaty compliance, and the ability to use the banking system in 
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APPENDIX: STATE LAWS AS OF NOVEMBER 9, 2016 
Table 2.   State Medical Marijuana/Cannabis Program Laws235 

















(1998) SB 94 
(1999) Statute 
Title 17, Chapter 
37 
Yes No Yes  Ballot Measure 2 (2014) Not yet operational 
Arizona Proposition 203 (2010) Yes Yes Yes Yes   
California 
Proposition 215 














(2000) Yes Yes Yes No 
Amendment 64 (2012) 
Task Force Implementation 
Recommendations (2013) 
Analysis of CO Amendment 
64 (2013) 
Colorado marijuana sales 
and tax reports 
2014 “edibles” regulation 
measure 
Connecticut HB 5387 (2012) Yes  
Yes 
Yes    






Yes Yes Yes  
Initiative 71 (2014) 
Pending congressional 





Nov. 2014, not 
yet operational. 
Yes Yes Yes No   
Hawaii SB 862 (2000) Yes No Yes    
Illinois 
HB 1 (2013) Eff. 
1/1/2014 
Proposed rules 
as of April, 2014 
Yes Yes Yes No   
                                            
235 Source: National Conference of State Legislatures, “State Medical Marijuana Laws.”  
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(1999) LD 611 
(2002)  
Question 5 
(2009) LD 1811 
(2010) 
LD 1296 (2011) 
Yes Yes Yes Yes   
Maryland 
HB 702 (2003) 
SB 308 (2011) 
HB 180/SB 580 
(2013) HB 1101- 
Chapter 403 
(2013) 
SB 923 (signed 
4/14/14) 
HB 881- similar 
to SB 923 






Yes Yes Yes    
Michigan Proposal 1 (2008) Yes 





allow them and 
regulate them. 
Yes Yes   




Yes    
Montana 
Initiative 148 
(2004) SB 423 
(2011) 
Yes No** Yes No   
Nevada 
Question 9 
(2000) NRS 453A 
NAC 453A 
Yes No Yes    
New Hampshire HB 573 (2013) Yes Yes Yes 







own in NH. 
  
New Jersey 
SB 119 (2009)  
Program 
information 
Yes Yes Yes    
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State Allows for Retail 
Sales/Adult Use 
New Mexico 













than 10 mg of 
THC, product 
may not be 
combusted 
(smoked). 





SB 161 (2007)  
Yes No Yes  Measure 91 (2014)  Not yet operational 
Rhode Island SB 791 (2007) SB 185 (2009) Yes Yes Yes Yes   
Vermont 
SB 76 (2004) SB 
7 (2007) SB 17 
(2011) 





SB 5073 (2011) 
No 
Yes, approved 
as of Nov. 2012, 
stores opened 
in July, 2014. 
Yes  
Initiative 502 (2012) 
WAC Marijuana rules: 




Table 3.   Limited Access Marijuana Product Laws  
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